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Chronic rhinosinusitis (CRS) is defined by the symptomatic inflammation of the nose and paranasal 
sinuses longer than 12 weeks. These symptoms include nasal discharge, nasal obstruction, facial 
pain and pressure, leading to a substantial impact on the quality of life of CRS patients. CRS can 
be phenotypically classified into either CRS without nasal polyps (CRSsNP) or CRS with nasal 
polyps (CRSwNP), based on the presence of endoscopically visualized nasal polyps in the middle 
meatus. Interestingly, ectopic accumulations of lymphoid cells are often observed within the nasal 
polyps of CRSwNP. This raises the question as to whether these aberrant lymphoid cell aggregates 
play a role in orchestrating the perpetual inflammation in CRS. Studies in the past have identified 
the increased amount of local class-switched antibodies in nasal polyps, but few studies have 
investigated the source of these immunoglobulins and utilized specific markers to study the 
presence of the organized lymphoid structures and their relation to disease severity in the context 
of CRS. This thesis investigates the significance of organized lymphoid neo-organogenesis in CRS 
pathogenesis and its effect on humoral immunity within both CRSsNP and CRSwNP patients.  
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Chapter 1: Introduction 
1.1 Background 
Definition of Chronic Rhinosinusitis 
According to the most updated European Position Paper on Rhinosinusitis and Nasal Polyps 
(EPOS) published in 20121, Rhinosinusitis is defined as inflammation of the nose and the paranasal 
sinuses characterized by at least two symptoms, which comprise at least one from each of the two 
must-have categories of signs and symptoms. The first must-have sign/symptom category consists 
of nasal blockage/obstruction/congestion and nasal discharge (anterior/posterior nasal drip), ± 
facial pain/pressure, ± reduction or loss of smell. The second must-have sign/symptom category 
consists of endoscopic signs of polyps or mucopurulent discharge primarily from middle meatus 
or oedema/mucosal obstruction primarily in middle meatus, and CT changes showing mucosal 
changes within the ostiomeatal complex and/or sinuses. When these symptoms last for 12 weeks 
or more in adults, the disease is defined as Chronic Rhinosinusitis (CRS)1, 2 and its definition 
remained unchanged in the latest EPOS update1.  
Prevalence of CRS 
CRS is a highly impactful disease worldwide with high prevalence in the general population.  
Up to 10.5% of the Australian population is affected by CRS3. In the United States, a household 
survey was conducted in 2012 and the prevalence of CRS was found to be 16%4. The actual 
question regarding the prevalence of CRS was “In the last 12 months, has the patient had sinusitis 
diagnosed by a doctor or a health professional?”4. In the European populations, there were found 
to be substantial variations in the prevalence of CRS between countries5. In 2011, the Global 
Allergy and Asthma European Network project (GA2LEN) performed a multi-centre study which 
included 19 centres in 12 European countries. The study revealed that the self-reported doctor-
diagnosed CRS ranges from 1.1% (Umea, Sweden) to 18.1% (Coimbra, Portugal) whereas the self-
reported CRS by EPOS 2007 criteria ranges from 6.9% (Helsinki, Finland and Brandenburg, 
Germany) to 27.1% (Coimbra, Portugal)5. There was a statistically significant association between 
the self-reported doctor-diagnosed CRS and the self-reported CRS by EPOS criteria. These 
findings reflected, to a certain extent, that there is true geographical discrepancy in the prevalence 
of CRS across these cities. In Sao Paulo, the prevalence of CRS was found to be 5.51%, using a 
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complex two-stage cluster sampling plan and personal interviews which included EPOS criteria 
for defining CRS6. In South Korea, the Korean National Health and Nutrition Examination Survey 
2009 has found the prevalence of CRS, which is defined as the presence of nasal obstruction and 
nasal discharge lasting more than 3 months along with endoscopic evidence such as nasal polyps, 
to be 6.95%7. A follow-up study published in 2016 separated the overall prevalence of CRS into 
symptom-based CRS and endoscopy-based CRS, and the prevalence was found to be 10.78% and 
1.2% respectively. In China, the prevalence of CRS in 7 major cities is found to be 7.99% using 
the standardized questionnaire developed by GA2LEN8. Due to the need for surgery and frequent 
recurrence of the disease, it incurs billions of dollars of health care expenses per year9. 
Classification of CRS 
 CRS patients are phenotypically classified into CRS with nasal polyps (CRSwNP) or CRS 
without nasal polyps (CRSsNP). This is based on the presence of CRS with or without 
endoscopically visualized polyps in the middle meatus1. Despite the considerable overlap between 
CRSwNP and CRSsNP in terms of clinical presentation10, 11, treatment options and treatment 
efficacy12, 13, there are a variety of differences in their respective inflammatory profiles14, 15 and 
treatment outcomes16. Although current knowledge of polyp development is very limited, the 
presence of polyps is useful for differentiating the two groups in many aspects. CRSwNP patients 
tend to have a more pronounced nasal obstruction and loss of smell whereas headache and postnasal 
drip is more common among CRSsNP patients 17. At cellular and molecular levels, CRSwNP has 
a distinctive immune cell activation and cytokine expression profile in comparison with CRSsNP. 
These two CRS subgroups possess different clinical and morphological characteristics18, and they 
have fundamental differences in terms of the type of inflammation, orchestrating immune activities, 
tissue remodelling, risk of recurrence and co-morbidities18. 
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Figure 1.1 CRS phenotypes.  
CRS can be phenotypically classified into CRS without nasal polyps (A) and CRS with nasal 
polyps (B) based on the bilateral absence or presence of endoscopically visualized nasal polyps in 
the middle meatus. 
 
Current Treatment Options and disease recalcitrance 
Once a patient is clinically diagnosed to have CRS, the initial therapy is medical with oral 
antibiotics and topical or oral steroids. When medical therapy fails, the patients might be offered 
endoscopic sinus surgery (ESS). The purpose of the surgery is to remove diseased tissue, which is 
blocking sinus drainage passages and possibly cultivating infection, in order to restore normal 
functions in the sinuses19 (therefore, the previously used term functional endoscopic sinus surgery 
or FESS). ESS significantly improves the quality of life in most individuals20 and has a very high 
frequency of application worldwide. However, a conservative approximation of 10% of CRS 
patients do not respond well to ESS and develop refractory disease21. In CRSwNP, post-operative 
endoscopic examinations have found the rate of polyp recurrence up to 18 months after ESS to be 
approximately 60-70% and the risk factors of polyp recurrence include previous ESS and worse 
pre-operative polyposis severity22. Furthermore, in cases with more severe disease or when the 
outcomes were assessed by objective measurements, the failure rate of ESS can rise to as high as 
50%23. These CRS patients who do not respond to both medical treatments and surgical 
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interventions are defined as having recalcitrant CRS (rCRS). Revision surgery is frequently 
required for rCRS patients to provide mere symptomatic relief because there are no curative 
medical treatment options for these patients. This recurrent need for surgery in rCRS patients 
presents a substantial quality of life and economic burden. Therefore, new effective treatment 
options for rCRS are urgently needed. 
Co-morbidities and risk factors of CRS 
Asthma  
According to the National Institute of Health Guidelines on Asthma in 200724, asthma is 
defined as the following: “Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a role: in particular, mast cells, eosinophils, T lymphocytes, 
macrophages, neutrophils, and epithelial cells. In susceptible individuals, this inflammation causes 
recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night 
or in the early morning. These episodes are usually associated with widespread but variable airflow 
obstruction that is often reversible either spontaneously or with treatment. The inflammation also 
causes an associated increase in the existing bronchial hyperresponsiveness to a variety of stimuli. 
Reversibility of airflow limitation may be incomplete in some patients with asthma.” The GA2LEN 
has revealed that asthma was strongly associated with CRS consistently in all European centres 
(overall OR: 3.48; 95% CI: 3.21–3.77; test for heterogeneity P = 0.001) irrespective of age, gender 
and smoking behaviour25. Up to 70% of both severe and mild-to-moderate asthma patients are 
positive of rhinosinusitis by CT scanning26. Furthermore, the CT score of sinus mucosa thickening 
is significantly higher in the severe asthma group compared to the mild-to-moderate asthma group26. 
The risk of co-morbid asthma is increased in Th2-type CRSwNP in Caucasians
27, matching the 
usually Th2-skewed and eosinophilic inflammatory profile in asthma
24.  Intriguingly, sputum 
eosinophilia is an independent predictor of worse lung functions in severe asthma28 and medical or 
surgical treatments of CRS improve pulmonary functions of asthmatic patients29. These findings 
altogether suggest that asthma and CRS share common pathophysiology through Th2-mediated 
immunity, which could be the connection between sinonasal, upper and lower airway in a united 
airway concept30.  
Aspirin-exacerbated respiratory disease (AERD) 
Precipitation of asthma attacks after ingestion of aspirin (ASA) and non-steroid anti-
inflammatory drugs (NSAID) is considered the hallmark of Aspirin-exacerbated respiratory 
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disease (AERD), which is a clinical syndrome characterized by CRS, nasal polyposis and asthma31, 
32. The prevalence of AERD in adult asthma patients is 9 to 20%33, 34, tested by oral ASA challenges. 
In the subset of adult asthmatic patients with associated sinusitis and nasal polyposis, the 
prevalence of AERD increases to 33% to 40%35, 36. AERD patients have a much higher rate of 
nasal polyposis, up to 80%, compared to 4% in the general population37 and develop substantially 
more severe, long lasting and refractory CRS36, 38. Although the pathophysiological mechanisms 
of AERD have yet to be fully understood, it is well established that abnormal arachidonic acid 
metabolism is involved, leading to imbalanced cyclooxygenase (COX) and lipoxygenase 
pathways36. This anomaly leaves AERD patients with an overzealous lipoxygenase pathway which 
leads to an overproduction of leukotrienes upon ASA or NSAIDs intake, eventually setting off the 
precipitation of asthma attacks36, 39. There are multiple reports on elevated Th2 cytokines, including 
IL-4 and IL-1340, in CRSwNP patients with AERD, especially those involved in eosinophilic 
infiltration41, namely RANTES, eotaxin and eotaxin-2. 
Allergic rhinitis (AR) 
Allergic rhinitis (AR) is a heterogeneous disorder characterized by at least one of the 
following symptoms including sneezing, itching, nasal congestion and rhinorrhea42. AR is another 
manifestation of atopic syndrome, like asthma, associated with CRS43, 44 and it often co-exists with 
asthma45, 46, 47. The number of eosinophils is also increased in the bronchial mucosa of AR patients 
and, remarkably, in asymptomatic atopic individuals48, suggesting that aberrant immune activities 
precede the disease onset in atopic CRS patients. Furthermore, both AR and asthma feature a Th2-
type inflammation with increased IL-31 expression and elevated levels of serum eosinophils49. IL-
31 is a Th2 cytokine expressed by activated Th2 cells and is important in the development of both 
atopic and non-atopic dermatitis50. About 80% of children with atopic dermatitis develop asthma 
or AR51, implying a defective Th2-mediated immunity with the potential involvement of IL-31 
shared between asthma, AR, atopic dermatitis and possibly a subset of CRS. Such frequent co-
occurrence and similar inflammatory profile of asthma and AR suggest that there is a systemic 
immunologic cross talk between the upper and lower airway30. In terms of the CRS subtypes, the 
clinical association profile differs between CRSsNP and CRSwNP. Like asthma and aspirin 
sensitivity, co-morbid AR is associated mainly with CRSwNP 18, 52, 53 whereas CRSsNP is often 
associated with lower airway disease1. 
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Smoking 
 Smoking is a risk factor for CRS5 and many chemicals in tobacco smoke have been shown 
to be ciliotoxic (i.e. having high toxicity to respiratory cilia)54, 55, 56. Tobacco smoke exposure 
promotes inflammation and connective tissue breakdown57, 58. Coherently, it is evident in the 
literature that active smokers and individuals exposed to second-hand smoke are more susceptible 
to CRS59.  
1.2 Pathophysiology of CRS 
The one feature in common among all CRS subtypes is the chronic inflammation. However, 
the question as to the etiology underlying this chronic inflammation in an individual patient does 
not have a clear answer yet60.  
Persistent infections and the microbiome in CRS 
Microbial infections have long been proposed to play a role in the pathogenesis of CRS61, 
62. The concept of the disruption of symbiosis between commensal bacteria and humans, or 
dysbiosis, in the sinonasal mucosa might add clarity to how microbial infections are linked to CRS. 
Dysbiosis is defined as the change in the composition of residential commensal bacterial 
communities relative to those found in healthy individuals63. Dysbiosis in the gut is relatively well-
studied and restoring the healthy microbiome has been proposed to be a therapeutic application in 
some gastrointestinal diseases64. Fecal microbiota transplantation (FMT) has shown excellent 
therapeutic efficacy in treating recurrent Clostridium difficile infection64 and some initial success 
in treating inflammatory bowel disease65. In CRS, a literature review has shown that a large number 
of association studies have been done to demonstrate the different microbiomes between CRS 
patients and non-CRS controls66, indicating a dysbiosis in a subset of CRS patients67. Highlighted 
bacterial species with higher colonization rate in CRS include Staphylococcus aureus68, 69 and 
Pseudomonas aeruginosa69. Although the microbial communities are set to have a significant 
impact on CRS, the highly complex microbiological ecology, which includes interspecies and 
intraspecies communications as well as the potential influences from virus and fungi, renders the 
concept of a microbial etiology in CRS poorly understood70.  
Mucosal biofilms 
One of the proposed mechanisms that support the pathogenic role of bacteria in CRS is by 
forming biofilms. Bacterial biofilm is a mode of living characterized by cell attachment to a surface 
and encapsulation in a self-produced matrix of exopolymeric substances (EPS)71. This EPS matrix 
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physically shields the bacteria from external stresses (e.g. antibiotics), provides a scaffold for 
adhesion to a surface and cohesion between bacterial cells, and sequesters enzymes and nutrients 
important for survival71. Once bacteria enter this communal mode of living, the biofilm matrix 
provides a platform for cell-to-cell communication, exchange of genetic materials and the recycling 
of lysed cell materials72. Bacterial biofilms are commonly perceived as an adaptation to resist host 
defences and antibiotics in the setting of CRS, and thus foster recalcitrant disease73. Despite a 
research interest in the development of anti-biofilm therapies in CRS, a definitive causal 
relationship between CRS and biofilm, and the role of bacterial biofilms in the initial establishment 
of CRS have not been identified74. The potential pro-inflammatory property of S. aureus biofilms 
and whether it is linked to the initiation of CRS at the nasal epithelium warrant further investigation. 
While it is well known that bacteria in their biofilm form are much more persistent than 
their planktonic counterpart75, how bacterial biofilms generate a pathological chronic inflammation 
is less clear. In a general event of an acute infection, an inflammatory response is induced at the 
site of infection to initiate innate immunity against the invading pathogens. The innate immune 
system then calls for the more sophisticated adaptive immunity, which is slower but more specific 
to the antigen, through the help of bridging mediators and cells. A successful immune response 
would clear the acute infection and the resolution of inflammation would begin within the next few 
hours due to the high turnover rate of immune cells76. However, when the immune system fails to 
effectively clear an infection, it leads to a persistent infection where the inflammatory response is 
constantly being active and, consequently, gives rise to pathogenic chronic inflammatory 
conditions. An example of persistent infection leading to chronic mucosal inflammation is 
Helicobacter pylori infection at the gastric epithelium77. Forming biofilms is one of the ways that 
microbes use to evade or block immune responses against them. Biofilms, combined with host 
susceptibilities or niches for infection, are associated with the transition from transient to persistent 
infections71, 74. Therefore, understanding the host-microbial interactions, especially those within 
the microenvironment of the infection, is crucial to tackling the infection-associated chronic 
inflammation. As previously mentioned, one intensively studied bacterium central to CRS 
pathogenesis is Staphylococcus aureus, which has been identified in 64% of CRSwNP patients 
compared with approximately 30% of CRSsNP patients or healthy individuals 78. Evasive strategies 
to escape immunity by S. aureus include biofilm formation and intracellular invasion, which are 
extensively studied in CRS for their roles in helping the bacterium persist 79, 80. Although the exact 
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mechanisms underlying the self-perpetuating inflammation in CRS remain to be defined, our 
research group has found that the AIM2 inflammasome, which is a cytosolic dsDNA sensor and 
produces an inflammatory response when activated81, has consistently and significantly increased 
gene expression in CRSwNP patients and S. aureus biofilms 82. Given the association between 
biofilms and AIM2, one potential source of immunogenic microbial DNA is extracellular DNA 
(eDNA) in biofilms. The term eDNA used here is specific for DNA that forms the majority of the 
biofilm physical structure and is functionally active in favour of the microbes. Therefore, eDNA is 
distinctive from any free DNA, host or foreign, that exists outside the cells. Since the first 
demonstration of DNase I treatment on Pseudomonas aeruginosa leading to the dissolution of its 
biofilms in 2002 83, a wide range of bacteria have been subjected to DNase treatment and have 
shown the disruption of biofilms, especially at the early stage of biofilm development72.  In addition, 
eDNA also exists in fungal biofilms and plays a central role in biofilm formation84, meaning that 
eDNA is a well-conserved mechanism in biofilm biology. Although the importance of eDNA to 
the formation and integrity of biofilms has been undisputedly proven in many bacterial species, it 
is less clear as to how eDNA promotes biofilm formation and maintenance and, most importantly, 
how eDNA contributes to antibiotics resistance and pathogenic inflammation.  Mulcahy et al. have 
shown that in P. aeruginosa eDNA acts as a cation chelator to maintain a cation gradient, which 
triggers antibiotic-resistance genes to defend against cationic host-derived anti-microbial peptides 
and antibiotics (e.g. aminoglycosides) by modifying cell surface lipopolysaccharides (LPS) in 
order to conceal the negative charge of the bacterial outer membrane85. Apart from its chelating 
property, eDNA is also a core component of the bacterial quorum-sensing (QS) system, which is 
the mechanism by which bacteria detect the surrounding bacterial population density in order to 
adapt to the environment by regulating the expression of relevant genes86. Targeting eDNA as a 
means to disrupt QS has emerged as a promising method to mitigate biofilm-mediated pathogenesis. 
S. aureus has decreased biofilm formation and increased anti-microbial susceptibility when treated 
with recombinant human DNase I87. A study by Bass et al has also shown that P. aeruginosa lasI 
rhlI mutant strain, which has significantly reduced eDNA, has reduced ability to stimulate the 
release of IL-8 and IL-1β when co-cultured with neutrophils compared to wild-type strain88.  In a 
more recent study, inhibiting the target of RNAIII-activating protein (TRAP) QS systems89 in S. 
aureus using Hamamelitannin (2’,5’-di-O-galloyl-D-hamamelose; HAM) decreased the amount of 
eDNA present in the biofilm matrix and increased the susceptibility of S. aureus to vancomycin90. 
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In view of these findings, decreasing the load of eDNA within the biofilm matrix (e.g. direct 
digestion by DNase or inhibiting QS to limit the release of eDNA) has a promising potential in 
treating biofilm-associated infection. This is particularly important in fighting biofilm-forming 
microbes that are resistant to antibiotics such as Methicillin-resistant Staphylococcus aureus 
(MRSA). In the context of CRS, it is of particular interest whether S. aureus eDNA has the similar 
pro-inflammatory effects to the P. aeruginosa eDNA in stimulating immune cells88, especially 
eosinophils, given their prevalence and immunogenicity in CRS91, particularly CRSwNP92. 
Innate Immunity in CRS 
The epithelial barrier 
The sinonasal mucosa is in direct contact with the environment, meaning the exposure to 
inhaled allergens and irritants, and the colonization of both commensal and pathogenic organisms. 
Mucociliary clearance and apical junctional complexes (AJCs) between sinonasal epithelial cells 
serve as a mechanical barrier that protects the host from the environment. Goblet cells and 
submucosal glands produce respiratory mucus to trap foreign materials and remove them from the 
sinuses and nasal cavity. Both genetic and acquired defects in mucociliary flow have been linked 
to the disease process of CRS93, 94, 95. A disrupted tight and adherence junction, and thus a disrupted 
mucosal barrier, is associated with CRSwNP as demonstrated by significantly altered levels of 
adhesion molecules of AJCs96, 97, 98. Functional studies using an in-vitro air-liquid interface (ALI) 
model have shown that the epithelial barrier in CRSwNP is more permeable 98, 99, suggesting an 
increased susceptibility to infection in these patients with a defective epithelial barrier. An innate 
immune response is triggered through pattern recognition receptors (PRRs) when the epithelial 
barrier is breached15.  
Pattern recognition receptors 
Sinonasal epithelial cells are one of the cell types at the mucosal tissues that express 
PRRs100, 101, which recognize pathogen associated molecular patterns (PAMPs) from microbes. 
Some studies have suggested that Toll-like receptors (TLRs), which are the best-characterized 
PRRs, have potential defects that might contribute to the pathogenesis of CRS102, 103, 104, 105. TLRs 
are expressed by many cell types including epithelial cells, fibroblasts, endothelial cells and 
immune cells such as dendritic cells, macrophages, B cells and T cells106. TLR 1-9 are relatively 
well understood and have known agonists. TLR stimulation by their corresponding agonists is the 
strongest in TLR 3, 6 & 9 in primary nasal epithelial cells in vitro101. Each TLR has a distinctive 
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apical-basal polarization pattern in human airway epithelial cels107, indicating that airway epithelial 
cells have a significant role to play in regulating the innate immune response. 
TLR3 is expressed in the endosome of myeloid dendritic cells and macrophages whereas 
epithelial cells and fibroblasts can express TLR3 both intracellularly and on the cell surface108. 
TLR3 is mainly expressed on the luminal and basal mucosal surface of airway epithelial cells107. 
TLR3 recognizes double-stranded RNA (dsRNA), which is a PAMP associated with viral infection 
because it is produced by most viruses during replication109. When activated by poly(I:C), a 
synthetic dsRNA analogue, TLR3 transduces the signal through a MyD88-dependent signalling 
pathway to induce inflammatory cytokine production such as IL-6 and TNF-α109. MyD88 is an 
adaptor protein that is shared by all known TLRs109. TLR3 stimulation by poly(I:C) in human 
tracheal epithelial cells resulted in a strong induction of type I and type III interferons as well as 
pro-inflammatory cytokine IL-8107. 
TLR6 is expressed on the cell surface and it recognizes diacyl lipopeptide when coupled 
with TLR2110. The expression of TLR2 and TLR6 on airway epithelial cells have a predominant 
basolateral distribution107. TLR6 can also heterodimerize with TLR4 and recognizes oxidized low-
density lipoprotein (LDL) and amyloid-beta to produce sterile inflammation that is thought to be 
important for atherosclerosis and Alzheimer’s disease110. 
 As for TLR9, it is expressed by various immune cells including dendritic cells, 
macrophages, natural killer cells (NK cells) and other antigen presenting cells111. In human airway 
epithelial cells, TLR9 has a moderate surface expression with a clear luminal polarization107. TLR9 
recognizes the unmethylated CpG motifs, which are relatively common in the genomes of most 
bacteria and DNA viruses112. CpG motifs are generally suppressed and methylated in vertebrate 
genomes112. Nevertheless, a recent study has implicated that TLR9 may also recognize the CpG 
regions of host DNA exposed during apoptosis in autoimmune diseases where there is delayed 
clearance of apoptotic cells113. When activated in a MyD88-dependent manner, inflammatory 
cytokines such as IL-6, IL-12 and TNF-α, and type I interferon cytokines such as IFN-α are 
induced114. In the respiratory system, TLR9 activation reduces Th2-dependent allergic 
inflammation by inducing a Th1 response
115. E. coli DNA, but not human DNA, stimulates TLR9 
expressed on human large airways epithelial cells cultivated as air-liquid interface cultures to 
induce the dose-dependent release of IL-6, IL-8 and β-defensin 2 via the NF-κB pathway in a 
MyD88-dependent manner116.  TLR9 also plays a role in a variety of autoimmune diseases117 but 
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it appears to have protective effects in some autoimmune diseases while having detrimental effects 
in the others. In a murine model of systemic lupus erythematosus (SLE), TLR9 has regulatory 
effects on the development of lupus nephritis as shown by the loss of TLR9 exacerbating the 
autoimmune disease118. On the contrary, TLR9 activation has pro-inflammatory effects in erythema 
nodosum leprosum (ENL) as demonstrated by the TLR9 antagonist inhibiting the secretion of pro-
inflammatory cytokines by ENL PBMCs119. In CRS, TLR9 at the protein level is decreased in 
CRSwNP compared to non-CRS controls105 and this finding is consistent with the predominant Th2 
phenotype in CRSwNP. 
Nasal epithelial cells constitutively express and secrete a variety of host defensive 
molecules, with the levels of these molecules altered upon PRR stimulation120, 121, 122. Lowered 
expression of some defensive molecules, such as lactoferrin, psoriasin and calprotectin is 
associated with CRS122, 123, 124, but the underlying mechanisms are unclear. The reduced levels of 
anti-microbial molecules are likely to reflect the decreased number of submucosal glands, which 
is further supported by our histological observation of decimated glands particularly in CRSwNP. 
Besides these host defense molecules, sinonasal epithelial cells are also capable of secreting 
chemokines and cytokines to attract and activate innate lymphoid cells, respectively, in response 
to PRR stimulations120, 125, 126, especially the epithelial cells of nasal polyps127.  
The innate immune system plays a vital role in immune surveillance and coordinating the 
inflammatory response as a first-line defence, especially at the barriers that are constantly exposed 
to the external environment such as the airway epithelium, which is able to respond to a wide range 
of pro-inflammatory stimuli from both host and microbes by releasing various cytokines (e.g. IL-
5, IL-6, IL-8, etc.) 128.  Defective regulations of cytokines or mediators at the epithelium have 
critical effects in chronic inflammatory diseases, with examples including the airway epithelium in 
chronic obstructive pulmonary disease (COPD) and asthma 129, the intestinal epithelium in 
inflammatory bowel disease (IBD)130 and the salivary gland epithelium in primary Sjӧgren’s 
Syndrome (pSS) 131.  There is emerging evidence for the importance of epithelial innate immunity 
in inflammatory diseases 132, 133, 134 and TLR expression levels in epithelial cells are associated with 
inflammatory cytokine profiles 131. In the settings of the canonical pathway, the signal is transduced 
from TLRs to the nucleus by the NFĸb pathway, which regulates the gene expression of certain 
important downstream inflammatory mediators including inflammasomes and pro-inflammatory 
cytokine IL-1 135.  The inflammasome, which is a member of PRRs found in the cytoplasm, has 
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become a popular research area for inflammation and innate immunity studies since its discovery 
in 2002 136. In general, inflammasomes consist of a pattern recognition domain (e.g. Nod-like 
receptors in the NLR family or PYHIN in AIM2) and a caspase activation and recruitment domain 
(CARD) or an adaptor protein ASC that binds to CARD. The pattern recognition domain of each 
inflammasome is specific for a pro-inflammatory danger or damage signal (e.g. AIM2 detects 
cytosolic dsDNA81). The CARD domain cleaves caspase-1 into its mature form upon activation. 
Active caspase-1 in turn cleaves IL-1 into its active form and then the active IL-1 is secreted as 
a pro-inflammatory cytokine (figure 1). It is speculated that defects among these components of 
the inflammatory machinery in epithelial cells such as the NFĸb pathway are contributing factors 
to chronic inflammation137. The inflammasome protein itself can also be defective as shown by the 
study where AIM2 activation is achieved by the overexpression of AIM2 and inflammasome 
apparatus in otherwise inflammasome-deficient cells138. In non-canonical activation of AIM2, type 
I IFN is required and intracellular stimuli such as intracellular bacterial DNA from Francisella 
novicida has been shown to stimulate AIM2-mediated release of inflammatory cytokines IL-1β 
and IL-18139. AIM2 recognizes DNA in a sequence-independent manner but the DNA strands must 
be at least 80 bp long140. Activation of AIM2 results in pyroptosis141, which is a pro-inflammatory 
type of programmed cell death that leads to the release of damage associated molecular patterns 
(DAMPs), such as DNA, ATP, heat-shock proteins142, as well as IL-1β and IL-18143.  AIM2 is 
involved in the severe inflammation driven by microbial insults and autoimmunity144. In terms of 
bacterial infection, there is a range of bacterial species that can be recognized by AIM2 in immune 
cells144. Examples include AIM2-deficient macrophage in mice releasing reduced levels of IL-1β 
and IL-18 against infection by Listeria monocytogenes, Streptococcus pneumoniae and Francisella 
tularenesis145, 146, 147. AIM2-deficient THP-1 human monocytic cell lines have also shown reduced 
release of IL-1β against some bacterial infections such as Porphyromonas gingivalis and 
Mycobacterium tuberculosis148, 149. Interestingly, AIM2 plays a significant role in a murine model 
of acute central nervous system (CNS) infection by S. aureus150. Also, an increased colonization 
of S. aureus in CRSwNP78 has been shown to correlate with the increased AIM2 expression in 
CRSwNP and biofilm-positive patients82 but further investigations of their interactions in the 
context of CRS are needed. In the settings of inflammation derived from autoimmunity, AIM2 also 
plays a critical role in promoting chronic inflammatory conditions. Host DNA is not present in the 
cytosol under normal circumstances because it is normally sequestered in the nucleus or 
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mitochondria. However, individuals with genetic predispositions may have aberrant accumulation 
of host DNA in the cytosol caused by impaired degradation of DNA151 or excess uptake of 
extracellular DNA derived from neighbouring dying cells. This accumulated host DNA in the 
cytosol can serve as an endogenous danger signal, which can set off IL-1β release by activating 
AIM2 as in the AIM2-dependent pathogenesis of psoriasis152. In brief, given that AIM2 plays a 
pivotal role in driving inflammation derived from various origins and its expression being elevated 
in CRSwNP82 as mentioned above, it is speculated that AIM2 promotes severe inflammation in 
CRS. Nevertheless, it is not clear as to how AIM2 is activated and whether host-derived DNA or 




Figure 1.2 Inflammasome activation pathways in general 
Inflammasome activation requires a first signal of TLR ligation and an inflammasome-specific 
second signal. The activation leads to the cleavage of caspase-1 and subsequently cleavage and 
secretion of pro-inflammatory cytokine IL-1β and IL-18. Image adopted from Inflammasome 
Review (2012), Invivogen, http://www.invivogen.com/review-inflammasome (accessed on 25 Mar, 
18) 
Innate lymphoid cells (ILCs) 
 ILCs are the subjects of a rapidly expanding field of study in the realm of immunology 
and play an important role in autoimmune and inflammatory diseases153. ILCs can be categorized 
into group 1 to 3, each carrying a unique set of functions that ochestrate the type of immune 
response generated and the transition from innate to adaptive immunity154. Here we focus on 
group 2 and 3 ILCs due to their great relevance in CRS and the formation of lymphoid organs 
respectively. Group 2 ILC population comprises ILC2s, which can produce IL-4, IL-5 and IL-
13153, and are a potent driver of type II inflammation. Studies have shown that ILC2s play a 
decisive role in TH2 cell activities, in terms of both memory
155 and effector functions156. ILC2s 
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are activated by IL-25, IL-33 and TSLP157, 158, all of which can be produced by epithelial cells159, 
160, giving ILC2s an extra layer of importance given the emphasis on epithelium-mediated 
inflammation in this thesis. In CRS, our group has found that ILC2s are enriched in nasal 
polyps161 and these ILC2s are responsible for producing Th2 cytokines
162. Given the importance 
of Th2-type inflammation and its cytokines involved in CRSwNP, ILC2s are likely to contribute 
significantly to the pathogenesis of CRSwNP. Nonetheless, their precise role in the context of 
CRS and what therapeutic implications they can bring on remain to be elucidated. 
 Group 3 ILC consists of ILC3s and lymphoid tissue inducer (LTi) cells. ILC3s are a 
robust source of IL-17/IL-22163 whereas LTi cells are crucial to the initation of lymphoid organ 
formation164, 165. Currently, there is very limited evidence in the literature on the direct 
involvement of group 3 ILCs in CRS pathogenesis. However, given our research focus on 
lymphoid neo-organogenesis in CRS, LTi cells could be a relevant research target and their roles 
in CRS warrant further investigation. In murine lymph node and Peyer’s patch development, LTi 
cells were proven to be essential by knocking out RORγt166, which is indispensible for fetal LTi 
cell (CD4+CD3-IL-7Rα+ cell) functions. Another mouse model knocking out RORγ, the only 
different isoform of the same protein, yielded similar detrimental effects167. During fetus 
development, LTi cells are attracted to mesenchymal lymphoid tissue organizer (LTo) cells in the 
lymph node and Peyer’s patch anlagens through ICAM-1 and VCAM-1 expressed by both 
parties168. LTα1β2-expressing LTi cells then engage LTβR-expressing mesenchymal cells to 
induce lymph nodes and Peyer’s patches development168, 169. In the setting of lymphoid neo-
organogenesis, the involvement and necessity of LTi cells are still controversial164, 165. RORγt-
expressing LTi cells feature the production of IL-17170, 171, a characteristic property of group 3 
ILCs. This phenotype implicates an ancestral relationship between RORγt+ LTi cells and IL-17 
producing CD4+ Th17 cells
172. In the intestine, RORγt+ LTi cells are clustered in the 
cryptopatches between crypts of the intestinal lamina propria, where they govern the formation of 
isolated lymphoid follicles and produce IL-22172, which is a critical cytokine for the 
immunological activation of epithelial cells. This raises an interesting question as to whether the 
same interactions between LTi cells and epithelial cells take place at the respiratory tracts or 
sinuses. Adoptive transfer of adult LTi cells into CXCR5-/- mice induced the formation of 
intestinal lymphoid tissues170. However, some studies suggest that lymphoid tissue formation can 
be induced independently of LTi cells in response to infections173, 174. It is proposed that LTi cells 
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are substitutable by other immune cells in post-natal lymphoid tissue formation164, 165, 175 and this 
will be further discussed in later sections. 
Immune cells and extracellular traps 
Apart from the sensing of pathogenic patterns through the likes of TLRs and 
inflammasomes, it is also important to understand the effector cells in the innate immunity that 
directly give rise to the pathogenic inflammation and other symptoms in chronic inflammatory 
conditions. In the context of CRS, eosinophils have been highlighted in past studies as they are 
correlated with disease severity176, recurrence rate177, 178 and clinically distinct subsets of CRS179. 
In western countries, CRSwNP has a strong association with eosinophilic inflammation180, as 
represented by the eosinophilic markers eotaxin and eosinophil cationic protein (ECP)17. In contrast, 
CRSwNP in Asian countries is predominantly associated with neutrophilic inflammation but 
CRSwNP with eosinophilic infiltration has increased over the past few years180. Th2 cytokines such 
as IL-5 and eotaxin are essential in tissue eosinophilia180, 181 whereas neutrophilic infiltration is 
primarily associated with Th1 cytokines such as IFN-γ
182. The Th1/neutrophilic profile versus 
Th2/eosinophilic profile exemplifies the interplay between innate and adaptive immunity, which 
will be discussed in more details in the next section. The way that innate immunity and adaptive 
immunity influence each other to give rise to a particular phenotype in CRS, such as CRSsNP 
versus CRSwNP and neutrophilic versus eosinophilic inflammation, is not well understood thus 
warrants further investigation.  
In the past decade, there is an emerging interest in a new concept of immune cells releasing 
extracellular traps (ETs) to immobilize and kill microorganisms. ETs were reported for the first 
time in 2004 by Brinkmann et al where neutrophils released these web-like structures when 
encountering bacteria183. Due to the bactericidal effects of ETs, their composition and how they 
exert their functions have become a hot spot in the field of biomedical research. As for the structure 
of ETs, their backbone comprises DNA and histones binding a wide range of antibacterial 
molecules, including elastase, cathepsin G, bacterial permeability increasing protein (BPI) and 
myeloperoxidase (MPO) 183, 184, 185. Some of the antimicrobial properties of ETs are attributed to 
the reactive oxygen species (ROS) produced by the myeloperoxidase (MPO) on neutrophil ETs 
(NETs) with activated immune cells at the inflammation site as the source of hydrogen peroxide186. 
There are two modes of releasing ETs from an immune cell – with or without triggering a special 
form of programmed cell death called ETosis185, which features vacuolization and nuclear 
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chromatin decondensation with disintegration of the nuclear membrane187. In a non-ETosis 
scenario, neutrophilic vesicles containing ETs can travel across the cell membrane through budding 
to the extracellular space and then rupture to release their content188. In addition to chromosomal 
DNA, mitochondrial DNA can also be utilized to form ETs and be ejected by neutrophils189 and 
eosinophils190 but the mechanisms behind this peculiar way of ET formation are not clear. S. aureus 
has been reported to induce a rapid NET release without neutrophil lysis and the NET exhibited 
bactericidal effects188. After a prolonged exposure to pathogens, the nuclear envelope of 
neutrophils ruptured and the cells enter ETosis188, which is distinctive from other programmed cell 
death like apoptosis and does not require the activity of caspases187. The cell membrane of 
granulocytes undergoing ETosis erupt and release DNA mixed with granular content into the 
extracellular milieu185. Other cell types capable of releasing ETs include mast cells191, 
monocytes/macrophages192 and, notably, eosinophils193. Eosinophil ETosis (EETosis) can be 
triggered by a variety of stimulating factors including phorbol myristate acetate (PMA), cytokines 
with a platelet activating factor and, remarkably, immunoglobulins (IgG and IgA)194, 195. EETosis 
mainly occurs in inflamed tissues196 and EETs are thought to be involved in some chronic 
inflammatory diseases197 such as atopic dermatitis198 and allergies like allergic asthma199. 
The role of EETs in the characteristic eosinophilic inflammation in CRSwNP has been 
implicated by The Japan Epidemiological Survey of Refractory Eosinophilic Chronic 
Rhinosinusitis Study (JESREC Study). This multi-centre retrospective study, classified CRSwNP 
into eosinophilic CRS (ECRS) and non-ECRS in order to differentiate their refractory 
phenotypes178. Mucosal eosinophilia, which is defined as 70 eosinophils per high power field or 
higher178, significantly correlated with higher recurrence rates of polyps after surgery. ECRS with 
more severe mucosal eosinophilia was significantly associated with higher rates of recurrence. 
There are pronounced clinical differences between ECRS and non-ECRS200, particularly the highly 
viscous, glue-like mucous in ECRS. The massive eosinophilic infiltrates also account for the thick 
secretion observed in other persistent eosinophilic diseases including eosinophilic otitis media and 
allergic fungal sinusitis201, 202. Excessive amount of DNA was visualized in the eosinophilic mucin 
from an ECRS patient, where the DNA was confirmed to be EETs by immunostaining, indicating 
that EETs, in addition to mucin glycoproteins, are a major contributor to the high viscosity of the 
mucous in ECRS195. 
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1.3 Adaptive Immunity in CRS 
T cells and Th type immune response 
The adaptive immune system comprises different B cell and T cell subsets, which are 
equipped with different abilities and coordinate with each other in order to generate an appropriate 
type of immune response corresponding to the type of pathogenic challenge. The T helper cell, in 
particular, is a critical determinant of the type of mucosal inflammation in regard to neutrophilic 
versus eosinophilic predominance73. In CRS, the Th cell profiles are mostly Th1, Th2 and Th17
14, 17, 
depending on the polyp versus non-polyp differentiation and ethnicity. A Spanish cohort of 18 
CRSwNP patients had shown activated T cell infiltration expressing both IFN-γ and IL-5 
simultaneously, representing a mixed Th1/Th2 profile. This finding also suggests that the type of Th 
cell response is not predetermined and is likely to be influenced by the local immunological micro-
environment. In agreement with this study, a later study by Lam et al has demonstrated that Th17 is 
the default Th phenotype in healthy nasal mucosa whereas Th cells derived from nasal polyps 
express both Th2 and Th17 cytokines. By comparing the cellular and mediator profile of 10 CRSwNP 
patients and 13 CRSsNP patients in Belgium17, Th2 cytokine IL-5 was highly upregulated in 
CRSwNP patients but not in CRSsNP patients or healthy controls whereas Th1 mediator IFN-γ was 
upregulated in CRSsNP patients only. The Th2-dominant response in CRSwNP is consistent with 
the fact that S. aureus is prevalent in CRSwNP and a major driver of Th2 response 
203, 204. TSLP, 
another cytokine favouring a Th2-type immune response, was also found to be elevated in 
CRSwNP205. A more recent study has shown that a subset of Th2 effector cells that express receptors 
for Th2 cytokines IL-25 and IL-33 were only present in CRSwNP but not in non-CRS controls
206. 
These cells can respond to IL-25 and IL-33 to give an elevated IL-5 and IL-13 production, therefore 
augmenting the Th2-response specifically in CRSwNP
206. When these findings appear to suggest 
that CRSwNP and CRSsNP are mediated by Th2 and Th1 response respectively in a clear-cut fashion, 
eotaxin and eosinophil cationic protein (ECP), which are involved in eosinophil chemotaxis and 
degranulation respectively, are upregulated in both CRSwNP and CRSsNP patients compared to 
healthy control with the degree of upregulation being much higher in CRSwNP 17. Since 
eosinophils are activated by Th2 cytokines 
207 thus represent a Th2 response, it is speculated that a 
subset of CRSwNP and CRSsNP patients are at different progressive stages of CRS where the 
immune response shifts from type I to type II as a consequence of eosinophilic infiltration during 
nasal polyp development. In our study, we have found that tissue eosinophilia in CRSwNP patients 
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(n = 75) is more than twice as prevalent as in CRSsNP patients (n=59)208, supporting the notion 
that inflammation in CRSwNP is predominantly eosinophilic and T h2-skewed. Nevertheless, a 
Th1/Th17 cytokine profile and neutrophil predominance is observed in Southern-Chinese CRSwNP 
patients in contrast to the Th2 predominance in Belgian CRSwNP patients as shown in the study by 
Zhang et al 14, suggesting that the association between Th2 and nasal polyposis may not be causative 
and complications such as ethnicity and geographical distribution need to be taken into account.  
Infections are also one of the contributing factors to the Th1/Th2 polarization
73. 
Superantigens can skew the cytokine profile towards a Th2 response as in S. aureus enterotoxins in 
CRSwNP27. The previously discussed S. aureus biofilms could also favour a Th2 response 
independent of the superantigen effect209. In addition, microbes might manipulate the adaptive 
immunity to produce a mal-adaptive Th2-skewed immune response in order to reduce innate 
immunity at the epithelium and consequently facilitate infection in CRS 105, 210. To summarize, the 
Th endotypes in CRS are determined by a variety of highly complex and continuous interactions 
between host factors (e.g. predisposition to lymphoid neo-organogenesis and ethnicity) and 
environmental factors (e.g. superantigens and biofilms). The question as to why Th2 response is 
associated with nasal polyposis in the western population is currently unclear and warrants further 
investigation. 
B cells 
Apart from the differential T helper cell profiles between CRSwNP and CRSsNP, there are 
also increased B cell activities in CRSwNP compared to CRSsNP. The number of CD138+ plasma 
cells was significantly increased in CRSwNP compared to CRSsNP and non-CRS control17. The 
expression of B cell-activating factor of the TNF family (BAFF), a potent regulator of class-switch 
recombination and immunoglobulin production, is also elevated in CRSwNP211 and this could be 
a contributing factor to the increase in plasma cell number. More CD19+ cells were observed in 
CRSwNP compared to CRSsNP and control but not CRSsNP versus control212, indicating that there 
are germinal centre reactions and B cell maturation specifically to the CRSwNP phenotype. 
Coherently, there were increased local, but not systemic, class-switched immunoglobulins, 
including IgG, IgA and IgE in CRSwNP versus CRSsNP212. The immunoglobulin overproduction 
in CRS might be related to bacteria since 71% of CRSwNP and 57% of CRSsNP patients possess 
bacteria-specific IgE as compared to 10% in allergic rhinitis213. The association between bacteria 
and the increased humoral immune response in CRSwNP is further supported by the fact that 
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specific IgE antibodies against staphylococcal superantigens SEA and SEB have been detected in 
nasal polyps214. It is proposed that the overproduction of local IgE and IgA contributes to the 
inflammation in nasal polyps by activating mast cells and eosinophils215. There were signs of 
inducible, follicle-like lymphoid structures in the airway mucosa of nasal polyps216, 217, 218 and these 
lymphoid structures within the nasal polyps were later further characterized and confirmed, as 
tertiary lymphoid organs (TLOs), in our study208.  
1.4 Epithelial cells mediating Inflammation 
Given the increasing evidence for epithelial cells actively participating in immune 
surveillance and inflammation219, there is a rising interest in studying the innate immune 
mechanisms in mucosal surfaces and how they interact with pathogens and the “epimmunome”, 
that is all the factors in epithelial cells associated with immunology, in the initiation of 
inflammatory disorders. As for innate immunity in epithelial cells, the inflammasome is an 
important member of the epimmunome when it comes to inflammation. Inflammasome is 
expressed by many epithelial cell types such as intestinal, skin and airway epithelial cells and 
epithelial inflammasome mediates inflammation in multiple inflammatory disease models220. 
Strong induction of AIM2 has been observed in the lesions of psoriasis and atopic dermatitis152, 221, 
suggesting that AIM2 can induce severe inflammation at the epithelial barrier. Given that nasal 
epithelial cells can strongly express AIM2 inflammasome, which is a crucial factor for biofilm and 
polyp status in CRS82, the role of AIM2 produced by nasal epithelial cells in promoting the 
pathogenic inflammation in CRS became one of our research interests. Apart from inflammasome 
in the innate immunity arsenal, airway epithelial cells have also been shown to express TLRs with 
a clear apical-basolateral differentiation in each individual TLR107, demonstrating that epithelial 
cells possess the innate immune machinery which is well adapted to the exposure to pathogens of 
various types in the airway lumen. In functional terms, the agonists of TLR1/2, TLR3, TLR6 and 
TLR9 have the ability to stimulate primary human nasal epithelial cells to produce either IL-6 or 
IL-8101, showing that the innate immune machinery of airway epithelial cells is actively involved 
in mediating an inflammatory response. The versatility of the airway epithelium in innate immunity 
(Figure 1.3) has made them important inflammatory mediators132. Furthermore, airway epithelial 
cells (AECs) can also regulate the adaptive immunity by producing Th1 or Th2 cytokines. AECs can 
produce α-defensins 132, which serve as a chemoattractant of naïve CD4+ T cells, CD8+ T cells and 
immature DCs 222. α-defensins also induce the release of IFN-γ from T cells223, favouring a Th1 
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response. AECs can also promote Th2 type inflammation by producing TSLP
159, which is induced 
by TLR3 or Th2 cytokines stimulation. TSLP-stimulated myeloid DC (mDC) induce the 
differentiation of naïve CD4+ T cells into Th2 cells that produce IL-4, IL-13 and TNF-α but not IL-
10 and IFN-γ224, 225. Furthermore, TSLP is also one of the activators of cytokine-primed eosinophils 
to eject EETs226 and this is remarkable given the prominence of eosinophilic inflammation in 
CRSwNP. These immune-mediating properties coupled with being the physical barrier in direct 
contact with the lumen, nasal epithelial cells have become a promising target to study the initiation 
of inflammation in CRS. Given that AIM2 can detect bacterial DNA and the extracellular DNA 
(eDNA) within bacterial biofilms are theoretically in direct contact with nasal epithelial cells, it is 
hypothesized that eDNA, particularly when produced by S. aureus, is a potent inflammation driver 
via AIM2 and responsible for increased disease severity in CRSwNP. Nonetheless, AIM2-deficient 
mice are more susceptible to dextran sodium sulphate (DSS)-induced colitis, implicating that AIM2 
has a regulatory role in an inflammatory response227. This study has also shown that AIM2 exerts 
its regulatory effect by controlling the growth of opportunistic bacteria in the gut227, implying that 
an increase in AIM2 might favour microbes that are more resistant to inflammatory responses such 
as biofilm-forming S. aureus. One condition has to be met before the hypothetical AIM2 activation 
by eDNA can happen – bacterial DNA has to be internalized into the corresponding inflammation-
inducing cells in order to activate AIM2 in the cytosol. One mechanism that is central to the 
recognition of bacterial CpG-DNA and involves DNA internalization is the pathway controlled by 
two main proteins - high mobility group box 1 (HMGB1) and receptor for advanced glycation end-
products (RAGE). The members of HMGB protein family bind DNA at the minor groove228 and 
then exert their regulatory functions by increasing the affinity of the bound DNA to certain proteins, 
mainly transcription factors229. HMGB1, one of the damage associated molecular patterns, is 
secreted in response to pro-inflammatory stimuli230. Secreted HMGB1 binds to extracellular DNA 
in a structure-dependent (i.e. unmethylated CpG-DNA) rather than sequence-dependent manner229.  
The engagement of HMGB1-DNA complexes on RAGE expressed on the membrane of cells leads 
to the induction of IFN-α production in human peripheral blood mononuclear cells (PBMCs)231. 
AECs also can express HMGB1 and RAGE232, hence the treatment with CpG-DNA results in IL-
1β secretion in human bronchial epithelial cells232, presumably through HMGB1-RAGE 
interactions. HMGB-1 complexes with DNA and thus facilitates its internalization231 through 
endocytosis233 but whether RAGE is essential in the process is still in question231, 233. The 
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internalization of HMGB1-DNA complexes results in the activation of AIM2 in the cytosol, 
triggering pyroptosis in macrophages233 and eventually setting off an inflammatory response as 
discussed previously. Since airway epithelial cells also possess the necessary HMGB1-RAGE-
TLR9-AIM2 machinery, it is hypothesized that bacterial CpG-DNA derived from an infection can 
initiate inflammation at the nasal epithelium through the activation of AIM2. 
 
Figure 1.3 The repertoire of the innate immune mediators produced by AECs132 
1.5 Secondary lymphoid organs and tertiary lymphoid organs  
Overview of lymphocytes and lymphoid organs 
Lymphocytes are formed in primary lymphoid organs, which consist of the thymus and the 
bone marrow. After the creation at the bone marrow, the maturation of B cells also takes place in 
the bone marrow whereas T cells travel to the thymus where they become mature.  Some data 
suggests that Peyer’s patches and other gut-associated lymphoid tissues (GALTs) may also be 
involved in B cells maturation234. Lymphocytes precursors undergo V(D)J-recombination, which 
randomly determines the receptor gene segments an individual lymphocyte will express, and thus 
giving rise to the complementarity determing regions (CDR) of the receptor (i.e. the determinant 
of the specificity for an antigen). For T maturation, immature T cells undergo a positive selection 
process in which T-cells progenitors not interacting with major histocompatibility complexes 
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(MHC)-self-antigen complex will undergo apoptosis and be deleted from the selection235. MHC 
molecules are expressed on all nucleated cells and they function as a marker of “self” identity and 
present antigens to lymphocytes234. T-cells that bind to MHC-self-antigen complex with high 
affinity are also deleted to avoid autoimmunity, leaving only T-cell progenitors binding MHC 
molecules with low affinity to develop further. Next, these cells passing the positive selection 
undergo negative selection in which T-cells reacting with tissue-specific antigens presented by 
dendritic cells, macrophages and thymic epithelial cells on MHC molecules are removed to prevent 
auto-reactive T cells from developing235. As for B cell maturation, it starts in the bone marrow 
where immature B cells expressing B cell receptors (BCRs) with no or weak binding affinity to 
self antigen can become transitional B cells and travel to the spleen236. Splenic transitional B cells 
enter a second checkpoint for autoreactivity screening where only B cells with low binding affinity 
to self-antigens are allowed to migrate to germinal centres and differentiate into memory B cells 
or short-lived plasma cells with the support of T helper cells in the follicles236. Mature lymphocytes 
enter circulation and are activated when presented with the antigens they are specific for in 
secondary lymphoid organs (SLOs) such as lymph nodes and mucosa-associated lymphoid tissues 
(MALTs).  
SLOs provide a highly organized interface for antigen presentation to lymphocytes in order 
to generate an efficient immune response upon encountering a challenge by foreign antigens. SLOs 
develop in pre-determined locations with drainage from peripheral tissues. Entry of lymphocytes 
into SLOs is controlled by high endothelial venules (HEVs), which are blood vessels specialized 
in naïve lymphocytes binding and trans-endothelial trafficking into SLOs by expressing adhesion 
molecules and C-C motif chemokine ligand 21 (CCL21, a.k.a. secondary lymphoid tissue 
chemokine)237. There are very precise cell compartmentalizations within a SLO, orchestrated by 
chemokine-based homing of cells (i.e. cell migration towards a central spot) 237, that ultimately 
lead to the highly organized anatomy of SLOs. B cell homing is achieved by CXCR5-expressing 
B cells being attracted to CXCL13 expressed by B cell zone resident stromal cells whereas T cell 
homing is achieved by C-C motif chemokine receptor 7 (CCR7)-expressing T cells being attracted 
to T cell zone stromal cells expressing CCL21 and CCL19 (also called Epstein-Barr virus-induced 
molecule 1 ligand chemokine). Dendritic cells from the infected peripheral tissues translocate to 
the nearby draining SLOs, carrying the antigens derived from the infectious agent238. These mature 
DCs in SLOs become antigen-presenting DCs and interact with T cells in the T cell zone. T cells 
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specific for the presented antigens will be activated. Some activated Th cells migrate to the 
boundary between the B and T cell areas or differentiate into follicular T helper cells (Tfh) that 
move to germinal centres239. These Tfh cells provide support to B cells in T-dependent antibody 
responses239. Other activated T cells exit SLOs and travel to the inflamed site as effector cells237. 
Tertiary Lymphoid Organs 
The highly specialized and organized structures in SLOs can be induced in peripheral 
tissues, in the form of tertiary lymphoid organs (TLOs), when there is a persistent source of antigen 
and a constant need for extravasation of leukocytes as in zones of infection, transplant rejection 
and autoimmunity 165. The immunological functions of TLOs are very similar to those of SLOs. It 
has become well understood that when inflammation becomes a chronic condition, lymphocytic 
infiltrates increase gradually, and local plasma cells expand in numbers 165. While the functions of 
TLOs are meant to provide protective immunity as shown in peripheral lymphoid organ-knockout 
disease models240, 241, TLOs can also have detrimental effects when the enhanced immune response 
fails to clear the infection or targets self-antigens (or grafted tissues). There are a surging number 
of studies reporting the identification of TLOs in various chronic inflammatory or autoimmune 
disease models 164, 165, 242, including diseases that involve mucosal inflammation such as COPD 243, 
IBD 244 and Sjӧgren’s syndrome 245.  
In SLO formation, LTα12-expressing lymphoid tissue-inducer cells (LTi) bind LTR that 
is expressed on stromal cells to instruct them to develop into FDCs and HEVs246, 247. In the context 
of TLO formation, the instructive signal, that is LTα12-LTR binding, for lymphoid tissue 
neogenesis remains essential but the cell types carrying this signal are likely to be dendritic cells 
248, 249, which instruct naïve B cells to acquire LTi-like properties and interact with stromal cells 
250. Lymphocytes are also thought to be actively involved in the process of TLO formation251, 252. 
Subsequently, TLO construction is orchestrated by the chemokines (e.g. CXCL13 for B cells, 
CCL19/CCL21 for T cells) produced in accordance to stromal organization 241, 253. Recent studies 
have shown that Th17 cells constitute a part of this process as well
254, 255 and thus the Th17 pathway 
has emerged as an important target to study in the initiation of TLO development. For instance, a 
model of pulmonary inflammation induced by LPS has shown that IL-17 is a key mediator for the 
formation of inducible bronchus-associated lymphoid tissue (iBALT)256. Furthermore, Th17 cells 
inhibitor IL-27 has been shown to prevent TLO development in inflammatory arthritis by 
controlling CD4 T cell response257. Interestingly, IL-17 is dispensable in the formation of iBALT 
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in response to replication-deficient poxvirus modified vaccinia virus ankara258, implying that other 
cytokines belonging to the Th17 pathway can substitute IL-17 in inducing TLO formation. Recent 
studies have shown that other Th17 cytokines, namely IL-21, IL-22 and IL-23, also play a key role 
in TLO formation259, 260. However, there is yet to be a unifying theory encompassing the 
mechanisms of TLO formation and the variable degrees of structural organization of the infiltrates 
in different individuals. Although TLOs are induced in response to chronic inflammatory stimuli 
and thus can form theoretically in any inflamed non-lymphoid tissue, some tissues may have a 
higher propensity to develop TLOs than others261. Our data has shown that primary nasal epithelial 
cells can strongly express LTβ, BAFF and, intriguingly, IL-7Rα. When IL-7Rα heterodimerizes 
with the common cytokine receptor γ-chain (γc) or thymic stromal lymphopoietin receptor 
(TSLPR), the heterodimer recognizes IL-7 or TSLP respectively. The IL-7/IL-7R ligation enhances 
the expression of LTα12 in LTi cells, which are the main source of LTα12 signals for lymph node 
and Peyer’s patch development262. Similar to the requirement of LTα12, TLO development 
resembles that of SLO development as it also requires IL-7/IL-7R engagement263. IL-7R, but not 
IL-7, has significantly increased expression in CRSwNP patients compared to CRSsNP patients 
and is clustered with genes that are important for TLO development208. Therefore, it is inferred that 
epithelial cells can be a source of LTα12 to initiate TLO development, as in LTα12 -expressing 
LTi cells initiating SLO development, upon encountering foreign antigens. The ability of epithelial 
cells to produce these initiation signals might explain the propensity of TLO formation within nasal 
polyps.   
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Figure 1.4 Comparison of the signaling for SLO and TLO development175. 
 SLO initiation requires Lti cells to instruct LTo cells, through LTαβ-LTβR binding, to secrete 
chemokines for the contruction and organization of SLO. In TLO development, the initiation signal, 
LTαβ-LTβR binding, remains essential but LTi and LTo are replaced by relavant immune cells and 
peripheral tissue stromal cells respectively.   
 
Identification of TLO 
Neyt et al. proposed a set of criteria that can be used to define and identify TLOs 165 as 
follows:  
(i) the organized infiltrate contains anatomically distinct yet adjacent T and B cell compartments;  
(ii) the T cell area contains an extensive network of fibroblastic reticular cells (FRCs);  
(iii) PNAd+ high endothelial venules (HEVs) are present;  
(iv) evidence of B cell class switching and GC reactions in the B cell follicles;  
(v) AID enzyme, which is necessary for ongoing class-switching, is present;  
(vi) FDCs are present.  
It appears that organized structures partly fulfilling these criteria can still function as a TLO 165. 
TLOs can be identified, using immunohistochemistry, by demonstrating the clustering of B cells 
and FDCs within germinal centres and the presence of T cells and HEVs around the same follicles. 
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These combine to give the presence of necessary cell types and the high levels of organization 
between them in TLOs as required in the aforementioned criteria. This technique has been 
illustrated in other studies that successfully identified TLOs 264, 265. 
 
Figure 1.5 The structure of a TLO264  
There are B cell and T cell zones in TLO with HEVs sitting at the outskirt of the boundary of B & 
T cell zones. An active GC is located at the centre of a TLO and it consists of FDCs and GC-B 
cells. Unlike SLO, TLO is a very dynamic structure and, hence, some TLOs may not possess all of 
these features but still retain some TLO functions. 
 
TLOs in inflammation 
The significance of identifying TLOs is that they are closely related to the 
immunopathology in inflammatory diseases and autoimmunity. In a model of dextran sodium 
sulphate (DSS)-induced colitis in RORγT-negative mice (i.e. lacking programmed lymphoid 
tissues, LTi and Th17 cells) 
266, the immunity is mostly reliant on the generation of tertiary lymphoid 
tissues and the mice developed severe intestinal inflammation along with significantly more tissue 
damage upon DSS-introduced inflammation in the gut. This can be prevented by LTR 
immunoglobulin treatment that blocks the LTR receptor, indicating that TLOs are responsible for 
the severe inflammation observed in this disease model. Furthermore, the disease can also be 
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prevented by saturation of Fc receptors through intravenous immunoglobulin treatment, meaning 
that humoral immunity is crucial to the TLO-related immunopathology and this is coherent to the 
plasma cell expansion in TLOs. In a study that looked into immunologic memory in TLOs, memory 
B cells can be generated and maintained by TLOs independently of SLOs267. Since memory B cells 
are capable of responding to polyclonal stimuli such as CpG-DNA in the absence of BCR268 and 
thus differentiating into antibody-secreting cells in response to inflammatory signals, TLOs can 
sustain local antibody production through the memory B cells generated by them. In view of these 
findings, TLOs form in response to chronic insults (e.g. persistence infection, autoimmunity, graft 
rejection etc) and then promote severe local ongoing inflammation, which leads to further tissue 
damage, via GC activities and humoral immune response. The even more disrupted epithelial 
barrier becomes more susceptible to further infection269, causing the local inflammation to intensify 
and thus maintenance of TLOs. Therefore, it is hypothesized that a persistent source of 
inflammation, such as infections by biofilm-forming S. aureus, can set off a chronic inflammation 
that is maintained and aggravated by TLOs. A vicious circle of severe chronic inflammation is 
ultimately formed between the source of persistent inflammation, TLO formation, the 
inflammation-promoting TLO activities and the breached infection-prone epithelial barrier. The 
immunopathological role of TLOs has also been proposed in autoimmune diseases such as multiple 
sclerosis270, primary Sjögren’s syndrome 271, systemic lupus erythematosus (SLE) 272 and 
rheumatoid arthritis (RA) 273. In regard to autoimmunity, TLOs have a hypothetical role in 
facilitating a local breakdown of self-tolerance 271, 272, 273 due to intensive cell death and processed 
self-antigen presentation in the microenvironment of inflamed nasal mucosal tissues in CRS.  
 
Potential clinical implications of TLOs 
Given the contributions of TLOs to the pathogenic chronic inflammation in chronic 
infections and autoimmune diseases, TLOs have become an important biomarker for severe chronic 
inflammation and this has profound implications in the clinical value of TLOs. In rheumatic 
autoimmune diseases, TLOs have been extensively studied due to the increasing recognition of the 
importance of TLOs in the pathogenesis of these diseases274. In rheumatoid arthritis, frontline anti-
TNF biological therapies have a lower response in patients with TLOs in the synovial tissues 
compared to their TLO-negative counterparts275, demonstrating the prognostic values of TLOs. 
Interestingly, the phase III clinical trial of anti-IL-17 biologics Secukinumab has shown some 
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success in RA patients with inadequate response to anti-TNFα agents (clinical trial identifier: 
NCT01377012, information from the ClinicalTrials.gov website, accurate as of April 2017) and 
this could be related to the significant role Th17 cytokines play in TLO formation and maintenance. 
Furthermore, there are some promising results in animal models of arthritis276 and Sjögren’s 
syndrome277, where targeting LTβ using a LTβR-Ig fusion protein has led to the retardation of TLO 
development and disease amelioration. Nonetheless, translation of the beneficial effects of TLO-
specific therapies from animal models to clinical application presents to be a great challenge. The 
human LTβ blocker failed to clinically replicate the therapeutic efficacy in rheumatoid arthritis or 
Sjögren’s syndrome 278. It is speculated that the success in animal models is attributed to 
intervening TLO development at an early stage. However, patients receiving LTβ-targeted 
treatment would have relatively mature TLOs and thus the blockage of LTβ at this stage may have 
substantially diminished effects. Given the importance of B cells in TLO-mediated 
immunopathology, B cell depletion biologics might have therapeutic efficacy against relevant 
chronic inflammatory conditions. There are a number of ongoing or completed phase II or phase 
III clinical trials investigating the efficacy of drugs targeting BAFF in TLO-related autoimmune 
diseases like SLE and SS164, 274. Th17 cytokines IL-17 and IL-21 are also hotspots for clinical trials 
of biologics against rheumatic autoimmune diseases164, 274. Results of these clinical trials might 
shed light on the future of targeting TLO mediators as a novel therapeutic strategy. However, 
proper stratification based on TLO positivity is desperately needed in clinical trials since the 
prevalence of TLOs is low in these diseases (30-40% in RA279 and 27% in CRSwNP208). 
 
1.6 Potential autoimmunity in CRS 
 In general terms, self-antigens are inert to our immune system in a healthy individual owing 
to negative selection during lymphocyte maturation. Autoimmunity arises when lymphocytes start 
recognizing self-antigens and generate an immune response against them. It is still largely unclear 
why and how autoimmunity occurs but there are emerging hypothetical explanations such as 
defects in genes that are involved in the negative selection process like genes governing the 
selection checkpoints of BCR and T cell receptor (TCR)(e.g. autoimmune regulator, AIRE)280. 
Apart from defective negative selection genes, some infections could also trigger autoimmunity by 
means of molecular mimicry of self-antigen or superantigen281. In terms of molecular mimicry of 
self-antigen, when the structure of microbial peptides is sufficiently similar to that of self-peptides, 
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lymphocytes that are activated by those microbial peptides can also be activated by self-peptides, 
leading to autoimmunity282. Another mechanism by which autoimmunity can be caused by 
molecular mimicry is a process referred to as epitope spreading, which is defined as the 
diversification of epitope specificity from the dominant epitope on the immunogenic protein to 
other sub-dominant epitopes on the same protein283. These sub-dominant epitopes could be 
structurally similar to the epitopes of self-proteins, causing autoimmunity. As for superantigens, 
they are defined as a family of microbial proteins that have the ability to activate a massive number 
of T cells in a non-specific fashion so as to camouflage the microbes from the adaptive immunity 
in an infection284. Superantigens can activate up to 25% of an individual’s T cells285 whereas only 
less than 0.01% of the T cell repertoire would be activated via conventional MHC-restricted antigen 
processing284. The massive pool of activated T cells created by superantigen could include self-
reactive T cells, resulting in autoimmunity. Studies have found that CRSwNP is associated with 
the loss of tolerance in different forms like allergy and asthma. It has been shown that CRSwNP 
patients have increased local production of IgE against S. aureus enterotoxins217. IgE is a class of 
antibody that is closely related to allergic reactions due to its ability to sensitize basophils and mast 
cells by binding the receptors of these cells when activated by allergens286. Furthermore, there are 
signs of autoimmunity, which represents the loss of self-tolerance, being linked with CRSwNP. It 
has been shown that BAFF is upregulated in CRSwNP patients compared to CRSsNP patients and 
healthy controls211. BAFF plays a central role in class-switching and immunoglobulin 
production287 and the overexpression of BAFF in transgenic mice leads to major manifestations of 
autoimmunity288 such as sialadenitis that is reminiscent of pSS289.  Our research associates have 
identified that sicca symptoms (i.e. dryness in the eyes and mouth, typical symptoms of pSS) are 
associated with CRS and asthma in an epidemiological study290,  suggesting that sicca symptoms, 
possibly pSS, share common pathogenic mechanisms governing inflammatory diseases of the 
upper and lower respiratory tract. In a recent study that looked at a cohort of SLE patients, the 
presence of S. aureus in the nose was shown to be associated with increased production of anti-
nuclear autoantibodies (ANAs)291, which are a major manifestation of autoimmunity and are used 
as diagnostic markers of autoimmune diseases (e.g. anti-dsDNA for SLE, anti-Ro/La for pSS), and 
disease severity of SLE292. This suggests that microbial infection could be a trigger for 
autoimmunity or self-perpetuating inflammation. Since S. aureus can cause persistent infection at 
the sinuses and is closely associated with CRS pathogenesis, it is possible that S. aureus or other 
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persistent infections drive an ongoing inflammation which sets off a secondary autoimmunity in a 
subset of CRS patients. In studies that are relevant to autoimmunity specifically in CRS, CRSwNP 
patients were found to possess higher levels of class-switched immunoglobulins (IgG, IgE and 
IgA)211, 212. Furthermore, the levels of anti-dsDNA ANAs IgG and IgA, normalized to total IgG 
and IgA respectively, are elevated within the polyps compared to inferior turbinate mucosal tissues 
from CRSwNP, CRSsNP and non-CRS control291. These results altogether suggest that on top of 
the hyperimmunoglobulinemia observed in nasal polyps, the immune activities in the polyps, 
possibly from TLOs, specifically produce more ANAs, particularly anti-dsDNA. Tan et al. 
hypothesized that the chronic inflammation in the local mucosal microenvironment is facilitated 
by the expansion of autoreactive B-cell clones that helped perpetuating inflammation291. In the 
context of the higher incidence of ANA generation in CRSwNP, their hypothesis strikingly 
resonates with our TLO theory where germinal centres at the site of local inflammation may 
produce autoreactive B cells due to the release of pro-inflammatory signals from intensive cell 
death, processed self-antigen presentation during apoptosis or pyroptosis and the enhanced 
humoral immune response in the TLO. It is known that TLOs can be the local production sites of 
autoantibodies271, 293 and these autoantibodies are derived from the autoreactive B cells generated 
by the TLOs175. Examples include anti-citrullinated protein (anti-CCP) antibodies in rheumatoid 
arthritis273, anti-Sjögren’s syndrome antigen A (anti-SS-A) and anti-Sjögren’s syndrome antigen B 
(anti-SS-B) in Sjögren’s syndrome293, anti-thyroglobulin and anti-thryoperoxidase antibodies in 
Hashimoto’s thyroiditis, and anti-acetylcholine receptor antibodies in Myasthenia Gravis294. A 
recent study has looked at the therapeutic potential of stopping TLOs from generating ANAs by 
blocking IL-22259, which is a cytokine necessary for the differential expression of CXCL12 in 
epithelial cells and CXCL13 in fibroblastic stromal cells and thus crucial to B cell recruitment and 
organization in TLO formation. The blockade of IL-22 has led to the impairment of TLO formation 
and, consequently, the reverse of autoantibody production259, showing that TLOs can indeed 
produce ANAs and are a promising therapeutic target particularly in autoimmune diseases and 
possibly in a subset of CRS patients too. The theory where TLOs can induce autoimmunity would 
also explain why epithelial inflammatory diseases, as in the likes of pSS and asthma, are common 
co-morbidities in CRSwNP, given that epithelial cells are actively involved in mediating immune 
responses, both innate immunity and adaptive immunity295, and defects in these epithelial immune-
mediating pathways would ultimately contribute to the loss of tolerance through TLOs.   
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Chapter 2: Characterization of tertiary lymphoid organs in 















Background: Chronic Rhinosinusitis (CRS) is a persistent inflammatory condition of the sinus 
epithelium. Tertiary lymphoid organs (TLOs) have been found in severe chronic inflammatory 
diseases. However, their presence in CRS has not been demonstrated.  
 
Objective: To investigate the prevalence and the potential role of TLOs in CRS. 
 
Methodology: Sinonasal tissue along with detailed information on disease severity and clinical 
history was obtained from CRS patients with nasal polyps (CRSwNP), CRS without nasal polyps 
(CRSsNP) and non-CRS controls. mRNA was analysed using a microfluidic qPCR array, 
generating an expression profile of 29 TLO-related genes. Relative expression was determined by 
normalizing to 2 housekeeping genes and to non-CRS controls. Haematoxylin & Eosin stained 
tissue sections from 158 patients were analysed for the presence of TLO-like lymphoid aggregates 
and representative samples from the 3 groups were analysed by immunohistochemistry for the 
presence of TLOs.  
 
Results: TLOs were observed in 28/75 CRSwNP (37%), 6/59 CRSsNP (10%), and in 0/24 control 
patients. TLOs were exclusive to CRS patients compared to non-CRS controls (p = 0.002) and 
were 5.2-times more prevalent in CRSwNP than in CRSsNP patients (p = 0.003). 17 TLO-related 
genes had increased relative expression in CRSwNP patients (p<0.05). TLOs were associated with 
disease recalcitrance (p = 0.01), as defined by the number of previous operations, and with tissue 
eosinophilia (p = 0.003). 
 
Conclusions: Our data indicates that recalcitrant CRSwNP patients demonstrate massive 
inflammation with TLO formation in association with tissue eosinophilia. Analysis of matched 





Chronic Rhinosinusitis (CRS) is a common chronic inflammatory condition of the paranasal sinus 
mucosa, affecting approximately 10.5% of western populations 3, 4. CRS poses a heavy economic 
burden to the health care system owing to its high prevalence and need for surgery 9. Moreover, at 
least 10% of CRS patients do not respond to medical and surgical treatment regimens and develop 
refractory disease 21. CRS patients can be phenotypically classified according to the presence or 
absence of nasal polyps 1. CRS patients with polyps (CRSwNP) tend to have higher disease severity 
and risk of recurrence compared to patients without polyps (CRSsNP) 18. The self-perpetuating 
inflammation in CRSwNP is closely associated with persistent infections such as intracellular and 
mucosal biofilm-associated Staphylococcus aureus infections 79, 80, but the underlying mechanisms 
remain unclear.  
In order to generate an efficient immune response upon encountering antigen, the immune system 
has evolved to develop secondary lymphoid organs (SLOs) (e.g. Spleen, lymph nodes) present at 
specific anatomical localizations. SLOs allow intensive screening of pathogens in circulation or 
tissues and provide a highly organized interface for antigen presentation to lymphocytes. This kind 
of highly efficient and organized lymph node-like structure can also be induced, in the form of 
tertiary lymphoid organs (TLOs), when there is a persistent source of antigen and a constant need 
for extravasation of leukocytes as in zones of infection, transplant rejection and autoimmunity 165. 
TLOs are thought to play an important role in severe chronic inflammation and have been found 
in chronic obstructive pulmonary disease (COPD) 243, inflammatory bowel disease (IBD) 244 and  
Sjӧgren’s syndrome 245. It has become well understood that when inflammation becomes a chronic 
condition, lymphocytic infiltrates increase gradually and local plasma cells expand in numbers 165. 
Given that massive lymphocytic infiltration can be observed in CRSwNP patients and TLOs are 
commonly found in different severe chronic inflammatory conditions, it is hypothesized that TLOs 
are present in CRS.  
The purpose of this study is to determine whether TLO formation occurs in the sinonasal tissues of 
CRS patients using current histopathological criteria 165 as shown in Box 1. Using matched mRNA 
expression and immunohistochemistry from CRSwNP, CRSsNP and control patients, we 
determined the expression of genes known to be involved in TLO formation and maintenance. The 
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relationship of TLO formation to clinical data such as disease severity scores and tissue 
eosinophilia was also evaluated.  
2.3 Methods 
Patients and Samples 
This study was approved by the Human Research Ethics Committee of The Queen Elizabeth 
Hospital, Adelaide, Australia (reference number: HREC/15/TQEH/132). Biopsies were obtained 
from the ethmoid sinuses from patients undergoing endoscopic sinus surgery for CRS at the 
Department of Otolaryngology, Head and Neck Surgery, The Queen Elizabeth Hospital, Adelaide, 
Australia. Control patients were patients undergoing endoscopic skull base procedures without 
clinical or radiological evidence of sinus disease. CRS patients fulfilled the diagnostic criteria set 
out in the recent position papers by the American Academy of Otolaryngology and Head and Neck 
Surgery and the European Position Statement (EPOS) on CRS 296, 297. Patients with CRS were 
further sub-classified according the absence (CRSsNP) or presence (CRSwNP) of visible polyps 
present within the middle meatus on nasal endoscopy as defined by EPOS guidelines 296, 297. Nasal 
polyp tissues were obtained from CRSwNP patients and mucosal tissues were obtained from 
CRSsNP and control patients. Tissues for RNA extraction were placed in RNAlater (Sigma, St. 
Louis, USA) for 24 hours at 4˚C and then stored at -80˚C before total RNA preparation. Samples 
for immunohistochemistry were washed twice in 1x PBS and fixed in 10% neutral buffered 
formalin, followed by paraffin-embedding.  
Box 1. Definition and identification criteria of TLOs 
(i) The organized infiltrate contains anatomically distinct yet adjacent T and B cell 
compartments;  
(ii) The T cell area contains an extensive network of fibroblastic reticular cells 
(FRCs);  
(iii) Peripheral node addressin PNAd+ high endothelial venules (HEVs) are present;  
(iv) Evidence of B cell class switching and germinal centre (GC) reactions in the B 
cell follicles;  
(v) Activation-induced cytidine deaminase (AICDA), which is necessary for ongoing 
class-switching, is present;  





Paraffin-embedded tissue samples were cut in 4µm thickness, stained with Haematoxylin & Eosin 
(H&E) and scanned using digital whole-slide imaging (WSI) technology (NanoZoomer, 
Hamamatsu). Tissue eosinophilia was determined by averaging the number of eosinophils per High 
Power Field (HPF) (0.035 mm3) from at least 6 HPF’s/slide as specified by Ramezanpour et al 298.  
 
Immunofluorescence  
Tissue handling and processing were performed as described by Cantero et al 299. In short, formalin-
fixed paraffin-embedded tissue blocks were sectioned in 4µm thickness. Slides were de-
paraffinized and rehydrated. Antigen retrieval was induced at 100˚C for 10 minutes in 10mM 
sodium citrate buffer, pH 6. Slides were stained with various combinations of primary antibodies 
against the following human antigens using overnight incubation at 4˚C: mouse mAb L26 to CD20 
at 1:10 dilution (Abcam, Cambridge, UK); rabbit mAb EP3093 to CD21 at 1:50 dilution (Abcam, 
Cambridge, UK); rat MECA-79 to PNAd at 1:10 dilution (Biolegend, California, USA); mouse 
mAb PS1 to CD3 at 1:5 dilution (Abcam, Cambridge, UK). Control primary antibodies matching 
the species and antibody isotypes respectively with irrelevant binding specificity are the following: 
mouse IgG2a ICIGG2A to a synthetic hapten (Abcam, Cambridge, UK); rabbit serum IgG I5006 
(Sigma, St. Louis, USA); rat IgM RTK2118 to trinitrophenol (Biolegend, California, USA); mouse 
IgG1 MG100 isotype control (Invitrogen, Massachusetts, USA). The following fluorescent dye-
conjugated secondary antibodies were used at 1:200 dilutions: Alexa Fluor 488-conjugated 
polyclonal anti-mouse IgG (Jackson ImmunoResearch Laboratories, Pennsylvania, USA); Cy3-
conjugated polyclonal anti-rat IgM (Jackson ImmunoResearch Laboratories, Pennsylvania, USA); 
Alexa Fluor 647-conjugated polyclonal anti-rabbit IgG (Jackson ImmunoResearch Laboratories, 
Pennsylvania, USA). Cell nuclei were visualised with DAPI (4’,6-Diamidino-2-phenylindole 
dihydrochloride, Sigma, St. Louis, USA). Slides were incubated with Sudan Black solution 
(10mg/mL in ethanol, Sigma, St. Louis, USA) for 5 minutes to reduce auto-fluorescence. Slides 
were analysed with a Zeiss LSM700 confocal microscope. 
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Quantitative Real-time PCR  
Total RNA was prepared with TRIzol (Invitrogen, Massachusetts, USA) according to the 
manufacturer’s instructions; total RNA with RNA quality index 6.5 or above only, as determined 
by Experion RNA Analysis kit (Bio-Rad, California, USA), was allowed to proceed to cDNA 
synthesis; cDNA was synthesized from total RNA using Quantitect Reverse Transcription kit 
(Qiagen, Hilden, Germany). Biomark HD System (Fluidigm, California, USA) was used with 
Taqman chemistry (Applied Biosystems, California, USA) for all genes as instructed by the 
manufacturer’s protocol to perform qRT-PCR analysis. All cDNA was pre-amplified for 14 cycles 
before performing 35 cycles of 48x48 Dynamic Array Integrated Fluidic Circuit. 
 
Statistical analysis 
Gene relative expression was determined by the delta-delta Ct method according to Vandesompele 
2002 300. Ct values were normalised to endogenous control genes, B-actin and HPRT1, present on 
each PCR plate, and results for CRSsNP and CRSwNP patients were normalised to non-CRS 
controls Analysis was performed using R version 3.2.1 and the R library MCMC.qPCR 301. Full 
details, including the unique assay ID, for all proprietary primers used are listed on Table 2.2 in 
the supplementary data. 
 
Multivariate correlations between gene expression data was analysed by hierarchical clustering, 
using R library pvclust 302. The dendrogram was constructed from the Pearson correlation matrix 
of the log(expression) values (i.e. normalized to the endogenous control genes), using a distance 
measure of (1-|correlation|) and the complete linkage method, with subsequent bootstrapping to 
identify significant gene expression clusters. 
 
Associations between TLO and patient subgroups or clinical data within CRS patients were 
analysed by Monte Carlo simulated exact tests, by either exact logistic regression (R library elrm 
303 or other standard appropriate statistical tests from the R library coin304. All analyses within CRS 




Patient demographical data 
181 patients in total were included in this study. 68 were females and 111 were males (2 without 
data), aged 18 to 83 years old. The patients include 29 non-CRS controls, 69 CRSsNP patients and 
83 CRSwNP patients. Summary of demographic information is listed in table 2.1. 
Table 2.1 Summary of patient demographics 
  Control CRSsNP CRSwNP 








TLO 0/24 (0%) 6/59 (10.2%) 28/75 (37.3%) 
Asthma 1/24 (4.2%) 18/59 (30.5%) 42/75 (56.0%) 
Aspirin 
Sensitivity 0/24 (0%) 1/59 (1.7%) 10/75 (13.3%) 
Average 
Previous. OP 0 0.88 1.77 
Revision 
Surgery 0/24(0%) 27/59(45.8%) 49/75(65.3%) 
Eosinophilia 3/24 (12.5%) 22/59(37.29%) 61/74(82.43%) 
Oral Steroid* 3/24(12.5%) 2/59(3.4%) 6/75(8%) 
Antibiotics* 0/24(0%) 16/44(36.4%) 9/56(16.1%) 
Group Total 24 59 75 
*3 weeks prior to operation 
Relative expression of TLO-related genes in CRSwNP patients 
Data were derived from 2 PCR assays. Assay#1 had 21 CRSwNP patients, 17 CRSsNP patients 
and 7 controls. Assay#2 had 26 CRSwNP patients, 11 CRSsNP patients and 9 controls. 11 
CRSwNP patients, 10 CRSsNP patients and 6 controls were common to both assays. In the 
CRSwNP patient group, there was a significant increase in the mRNA expression of 17 genes 
including AICDA (fold-change = 8.79, 95% CI = (2.32, 32.45), p-value = 0.002), CCR7 (5.16, CI 
= (2.77, 8.41), p<0.001), CD274 (2.18, CI = (1.58, 3.15), p<0.001), CD40LG (3.94, CI = (2.78, 
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5.52), p<0.001), CXCL13 (4.12, CI = (0.63, 14.51), p=0.032), CXCR5 (11.57, CI = (4.81, 29.82), 
p<0.001), GPR183 (2.69, CI = (1.93, 3.92), p<0.001), ICAM1 (2.21, CI = (1.17, 4.32), p=0.024), 
IL-7R (3.22, CI = (2.33, 4.53), p<0.001), LTα (1.9, CI = (1.20, 3.03), p=0.002), LTβ (5.55, CI = 
(3.53, 8.74), p<0.001), PDCD1LG2 (2.18, CI = (1.58, 3.10), p<0.001), PDPN (1.54, CI = (1.15, 
2.23), p=0.014), SELPLG (4.43, CI = (2.48, 7.78),  p<0.001), RANKL (4.09, CI = (2.16, 7.67), 
p<0.001), BAFF (2.32, CI = (1.47, 3.89), p=0.002), VCAM1 (2.44, CI = (1.56, 3.81),  p<0.001) 
and a significant reduction in mRNA expression of 2 genes including RANK (0.31, CI = (0.15, 
0.59), p<0.001) and VEGF-C (0.61, CI = (0.44, 0.84), p=0.008). A comparison of the fold-changes 
between CRSwNP and CRSsNP for all genes with differential relative expression (p<0.05) in at 
least one of the two groups is shown in Figure 2.1. Relative expression details of all genes are 




Figure 2.1 Relative expression of differentially expressed TLO-related genes in CRSsNP and 
CRSwNP tissue 
Genes are grouped according to function into lymphocyte homing and compartmentalization (A), 
GC reaction and T-cell regulation (B), lymphangiogenesis and white blood cell recruitment (C), 
and lymph node development (D). Y-axes are plotted in log-2 scale. Error bars indicate the 95% 
CIs. *P ≤ .05 **P < .01, and ***P < .001 
 
Hierarchical clustering of TLO-related gene expression 
Hierarchical clustering of TLO-related gene expression (Figure 2.2) identified three clusters of 
genes which reached statistical significance, with 7, 2 and 7 genes in cluster 1, 2 and 3 respectively. 
Positively correlated genes within the same cluster were collectively either increased or decreased 
in the same patient. All genes in these clusters are positively correlated within the same cluster, 
except TNFRSF11A (RANK), which is negatively correlated with the rest of the genes in cluster 
1. Change in expression of each gene in all 3 clusters is statistically significant (p<0.05) in the 
CRSwNP group, except PDCD1 (p=0.12).  
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Figure 2.2 Hierarchical clustering of TLO genes based on expression 
Cluster dendrogram for correlations of the expression of TLO-related genes. Each dotted-line 
represents a cluster of genes that has statistically significant Pearson correlation (P < .05). 
 
GC-like structures are identified in sinus tissue from CRSwNP patients 
H&E stained sections of 24 controls, 59 CRSsNP and 75 CRSwNP patients were examined for the 
presence of TLO-like structures and number of eosinophils. A TLO-like structure was defined as 
an organised lymphoid structure present in the sinonasal mucosa as exemplified in Figure 2.3A. 
These were observed in 6 out of 59 CRSsNP (10%) and in 28 out of 75 CRSwNP patients (37%) 
but in none of the 24 control patients (Table 2.3). TLO-like structures are exclusive to CRS patients 
(p = 0.002, Fisher’s exact) and are more frequent in CRSwNP compared to CRSsNP (OR 5.2, 95% 
CI = 1.9, 16.7, p = 0.003). To confirm that these structures were indeed TLOs, we undertook an 
immunohistochemical analysis on tissue sections from representative patient groups that had 
suspected TLO-like structures (group 1: 5 CRSwNP, 1 CRSsNP) and those that did not (group 2: 
2 CRSwNP, 2 CRSsNP and 3 non-CRS controls). In our immunofluorescence analysis, only 
CRSwNP patients in group 1 possessed structures where FDCs were clustered with B cells to give 
a clear meshwork that resembled an active GC (Figure 2.3B). HEVs were observed in the T cell 
zone surrounding a putative GC (Figure 2.3C), matching the anatomical feature of a TLO.  
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Figure 2.3 Representative images of TLOs in patients with CRSwNP 
A) Hematoxylin and eosin staining showing a TLO (red circle) and tissue eosinophilia (black 
arrows in inlet). B, A highly organized TLO containing follicular dendritic cells (red) and B cells 
(green). C, Abundant high endothelial venules (red) and T-cell infiltration (green). Cell nuclei 
stained by 49-6-diamidino-2-phenylindole, dihydrochloride (blue). 
 
Associations of TLOs with clinical data, demographic factors and histological characteristics 
in CRS patients 
All analyses within CRS patients were stratified by patient subgroup. There was no association 
between the presence of TLO and age (p = 0.70), gender (p = 1.0), asthma (p = 0.37), or aspirin 
sensitivity (p = 0.72). However, TLOs were positively associated with tissue eosinophilia (OR 6.0, 
95% CI 1.5, 48.0, p = 0.003, exact logistic regression, stratified by CRS subgroup, Table 2.4). 
TLOs were also positively associated with the number of previous operations (p = 0.010, exact 
Wilcoxon-Mann-Whitney test, stratified by CRS subgroup, Table 2.5).  
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2.5 Discussion 
Our data strongly support the notion that TLOs are present within polyp tissue in a subset of CRS 
patients.  This is evidenced by our immunofluorescence analysis showing (1) that FDCs and HEVs 
were found exclusively in nasal polyp tissues in CRS patients but not in any of the control patient 
tissues; (2) that HEVs were found in the outer-follicle, corresponding to an important anatomical 
feature of a TLO 264; and (3) by our gene expression analysis, showing an upregulation in CRS 
patients of a number of genes that are essential in TLO formation and maintenance. Nonetheless, 
not all CRS patients had observable TLOs and in those who did, the degree of structural 
organization varied from one patient to another. Similarly, TLOs or TLO-like structures reported 
in other disease models have variable compliance of the proposed TLO definition (Box 1) 165. We 
speculate that a spectrum of structural organization of TLOs exists within CRS patients. Whether 
or not the extent of structural organisation associates with disease severity is unclear and warrants 
further investigation.  
 
There are profound implications of the presence of TLOs in CRS. In the context of infections, 
TLOs function as inductive sites for local protective immunity and disintegrate once the infection 
is cleared 240, 241. When the immune system is unable to clear the infection or there are frequent re-
infections, TLOs generate ongoing and often pathological humoral immune responses associated 
with significant tissue damage 241, 266, 267. Epithelial damage in turn facilitates bacterial infection 
and TLO formation, creating a self-perpetuating cycle of disease 259, 269.  Our finding of an 
association between TLO formation and a higher number of previous surgeries supports the notion 
that TLOs are associated with recalcitrant or more severe CRS. Further research will be needed to 
understand whether TLO formation in CRS patients negatively impacts on disease progression and 
severity. Deleterious effects of TLO formation are typically encountered in autoimmunity and 
transplant rejection. This is exemplified in Sjogren's syndrome 271, rheumatoid arthritis 273, 
autoimmune diabetes 305 and transplant rejections of different organs 306, 307, 308. In auto-immune 
diseases, TLOs can be the local production sites of anti-nuclear autoantibodies (ANAs) 271, 293. 
Interestingly, there is some evidence of autoantibody production, particularly ANAs,  within the 
polyps of CRSwNP patients 291. The association between local and systemic ANAs, TLO formation 
and CRS warrants further investigation. 
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The presence of TLOs in CRSwNP patients was found to be positively associated with tissue 
eosinophilia and eosinophils were observed both within TLOs and in the surrounding micro-
environment. The significance of this finding is not clear since, apart from infiltration of 
eosinophils as part of a general influx of reactive immune cells in the context of chronic 
inflammation and TLO formation, a specific association of TLOs and eosinophilia has not 
previously been reported.  It is well known that CRSwNP patients often have a predominant Th2-
type of inflammation with increased expression of Th2 cytokines and tissue eosinophilia 161, 309. It 
is also known that the airway micro-environment intrinsically favours the generation of Th2 types 
of responses. This is supported by the finding that T cell priming by intranasal delivery of a Th1-
inducing antigen promotes Th2-dominated responses with eosinophilia, rather than the expected 
Th1 responses 310. In a follow-up study by Constant et al, it was shown that these Th2 responses 
are critically dependent on the presence and activation of resident tissue CD11c+ Dendritic Cells 
(DCs) 311. DCs were furthermore shown to be essential for the organization and maintenance of 
inducible bronchus-associated lymphoid tissue (iBALT), a form of TLO induced in the lungs after 
influenza virus infection 241. In view of these findings, it can be hypothesized that our finding of a 
specific association of TLO formation and tissue eosinophilia might be dependent on the presence 
and activation of specific DC subsets. Further research will be needed to define the role of 
eosinophils in the context of TLO structure and function and potential common immune pathways 
of TLO-formation and tissue eosinophilia in the context of CRS. 
 
In our gene expression analysis, many genes that are critical to lymph node development were 
upregulated in CRSwNP patients, especially LTα, LTβ, IL-7R and RANKL. These results indicate 
that the TLO formation we observe here shares a number of the signalling pathways of lymph node 
development as reported 312 . Nevertheless, the inducing agents, instructive signals and cell types 
involved in TLO formation remain undefined. For instance, the involvement of LTi in TLO 
formation is still controversial 165. Gevaert et al suggested that organized lymphoid structures exist 
in nasal polyps of CRS patients with locally produced IgE against Staphylococcus aureus 
enterotoxins and increased eosinophilic inflammation 217. Given the association between TLOs and 
eosinophilia as described in our study, and the notion that S. aureus infections and biofilms are 
associated with worse prognosis and disease recalcitrance in CRS 209, it is likely that microbial 
antigens contribute to the formation of TLOs in CRS. Various infectious agents, such as 
48 
Helicobacter pylori 313, Influenza A 240and Epstein-Barr virus 314, have been shown to be associated 
with lymphoid neogenesis, however, a specific role for S. aureus in the induction of TLO formation 
has not yet been reported.  
 
We next examined correlations between relative gene expression to identify co-regulated networks 
relevant to TLO organogenesis 315. Our analysis generated 3 gene clusters, 2 of which were large 
enough (gene clusters 1 and 3, 7 genes each) to allow further assessment.  Gene cluster 1 consists 
of GPR183, PD-L2, PDPN, RANK, RANKL, BAFF and VCAM-1. These genes are mainly 
associated with committing stromal cells to lymph node development (PDPN, RANK, RANKL 
and VCAM-1) and functions related to T-cell-dependant humoral immune responses (GPR183, 
VCAM-1 and arguably PD-L2). Two genes are more ambiguous in terms of fitting to these 
functions. First, BAFF enhances B cell survival and boosts humoral immune responses presumably 
in a general fashion, rather than being dedicated to T-cell-dependant humoral immune responses 
316. The fact that BAFF also fell within this gene cluster may point to the involvement of type I 
IFN as in other inflammatory diseases 317, 318. Second, PD-L2 is expressed on professional APCs 
and has anti-proliferative effects on CD4+ T cells when bound to PD-1 319. Although it appears to 
be an immunosuppressive gene as PD-L2-deficient mice suffer from loss of tolerance 319, a more 
recent study had found that PD-L2 also inhibits CD4+ FOXP3+ T regulatory cell (Treg) homing to 
lymph nodes 320.  
 
Gene cluster 3 consists of AICDA, CD40LG, CXCL13, CXCR5, IL-7R, LTα and LTβ. These 
genes are all strongly linked to B cell follicle development, homeostasis and functions and give 
rise to GC reactions and class-switched antibody production. LTα1β2 is a crucial instructive signal 
for lymphoid organogenesis by activating two NF-κB pathways 321, which in turn activate the 
transcription of important TLO-related genes such as VCAM-1, CXCL13 and BAFF. Mice lacking 
LTα or LTβ have disrupted FDC-B-cell networks and thus underdeveloped GCs due to the loss of 
LTα1β2 
322, 323. LTα1β2-expression is enhanced by IL-7-IL-7R signalling 
324, which is essential for 
lymphoid follicle formation as a result. IL-7R is expressed on germinal centre B cells only when 
they are activated 325. IL-7R is also expressed in late follicular T helper cells (Tfh) 
326, which, 
through the expression of CD40LG 239, play a central role in the selection of GC B cells that then 
become plasma cells and produce class-switched antibodies 327. Mice lacking CD40LG or CD40 
49 
have impaired class-switching and GC formation 328, 329. Hence, the fact that IL-7R was found 
elevated in our gene expression analysis justifies the follicle-related properties of these genes. 
Another core gene for affinity maturation and class-switching, AICDA 330, also belongs to this 
gene cluster. The importance of AICDA to TLO-related pathology has been exemplified in chronic 
inflammatory diseases as in infections 331 and autoimmune diseases 273, 332. CXCL13 is expressed 
by FDCs to attract B cells that express CXCR5, the receptor for CXCL13, providing the basis for 
B cell homing. Furthermore, CXCL13-CXCR5 interaction promotes LTα1β2 expression on B cells 
to give a positive feedback loop, reinforcing B cell follicle formation and homeostasis 333. Based 
on these associations, we propose that CRS patients with high levels of cluster 3 genes are likely 
to have more mature forms of TLOs (i.e. at the structurally organized end of the TLO status 
spectrum) and, therefore, more likely to have recalcitrant disease after surgery. 
 
2.6 Conclusion 
The presence of TLOs in CRS patients has been demonstrated by immunofluorescence and gene 
expression studies. Analysis of a cohort of 158 patients with matching histology and clinical data 
has shown that TLOs are positively associated with tissue eosinophilia and the number of previous 
operations. The gene expression profile suggests that CRS patients could be at different progressive 
stages of the disease, which are reflected by the TLO status.  Our data suggests that TLOs may 
have prognostic value in predicting the chance of disease relapse. Targeting the triggers and 
molecular pathways that govern TLO formation and maintenance may help alleviate the ongoing 
severe inflammation in recalcitrant CRS.  
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2.7 Supplementary data 
Table 2.2 Details of all primers used in the microfluidic qPCR assay 
Assay ID Gene 
Symbol 
Gene Name 
Hs01060665_g1 ACTB beta actin 
Hs02800695_m1 HPRT1 hypoxanthine phosphoribosyltransferase 1 
Hs00989654_g1 CCL21 chemokine (C-C motif) ligand 21 
Hs00171149_m1 CCL19 chemokine (C-C motif) ligand 19 
Hs01013469_m1 CCR7 chemokine (C-C motif) receptor 7 
Hs01099203_m1 VEGFC vascular endothelial growth factor C 
Hs00266645_m1 FGF2 fibroblast growth factor 2 (basic) 
Hs00300159_m1 HGF hepatocyte growth factor (hepapoietin A; scatter factor) 
Hs00174202_m1 IL7 interleukin 7 
Hs00233682_m1 IL7R interleukin 7 receptor 
Hs00921372_m1 TNFRSF11A tumor necrosis factor receptor superfamily member 11a; 
RANK 
Hs00243522_m1 TNFSF11 tumor necrosis factor (ligand) superfamily member 11; 
RANKL 
Hs03676656_mH CXCL12 chemokine (C-X-C motif) ligand 12 
Hs00757930_m1 CXCL13 chemokine (C-X-C motif) ligand 13 
Hs01003372_m1 VCAM1 vascular cell adhesion molecule 1 
Hs00164932_m1 ICAM1 intercellular adhesion molecule 1 
Hs00366766_m1 PDPN podoplanin 
Hs00757808_m1 AICDA activation-induced cytidine deaminase 
Hs00153368_m1 BCL6 B-cell CLL/lymphoma 6 
Hs00163934_m1 CD40LG CD40 ligand 
Hs04276253_m1 SELPLG selectin P ligand 
Hs00270639_s1 GPR183 G protein-coupled receptor 183; EBI2 
Hs01125301_m1 CD274 CD274 molecule; PD-L1 
Hs01057777_m1 PDCD1LG2 programmed cell death 1 ligand 2; PD-L2 
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Assay ID Gene 
Symbol 
Gene Name 
Hs01550088_m1 PDCD1 programmed cell death 1; PD-1 
Hs00198106_m1 TNFSF13B tumor necrosis factor (ligand) superfamily member 13b; 
BAFF 
Hs00242739_m1 LTB lymphotoxin beta 
Hs04188773_g1 LTA lymphotoxin alpha 





This publication has been cited by: 
 
➢ Sokoya M, Ramakrishnan VR, Frank DN, Rahkola J, Getz A, Kofonow JM, Nguyen Q, 
Janoff EN. Expression of immunoglobulin D is increased in chronic rhinosinusitis. Annals 
of Allergy, Asthma & Immunology. 2017 Oct 1;119(4):317-23.  
 
➢ Song J, Wang H, Zhang YN, Cao PP, Liao B, Wang ZZ, Shi LL, Yao Y, Zhai GT, Wang 
ZC, Liu LM. Ectopic lymphoid tissues support local immunoglobulin production in patients 
with chronic rhinosinusitis with nasal polyps. Journal of Allergy and Clinical Immunology. 
2017 Nov 3 
  
53 
Table 2.3 Relative expression of genes tested in the qPCR assay 















actin 1       1       
AICDA 3.30 0.65 13.76 0.114 8.79 2.32 32.45 0.002 
BCL6 0.90 0.55 1.56 0.670 0.87 0.53 1.37 0.524 
CCL19 1.52 0.63 4.11 0.362 1.44 0.60 3.17 0.398 
CCL21 1.25 0.53 3.45 0.614 0.77 0.36 1.71 0.522 
CCR7 2.37 1.15 4.40 0.018 5.16 2.77 8.41 <0.001 
CD274 1.15 0.77 1.70 0.524 2.18 1.58 3.15 <0.001 
CD40LG 2.89 1.97 4.38 <0.001 3.94 2.78 5.52 <0.001 
CXCL12 1.44 0.78 2.92 0.26 0.73 0.41 1.22 0.27 
CXCL13 3.24 0.63 14.51 0.140 4.12 1.03 13.60 0.032 
CXCR5 3.66 1.32 9.43 0.012 11.57 4.81 29.82 <0.001 
FGF2 1.28 0.90 1.96 0.218 0.78 0.56 1.10 0.174 
GPR183 1.73 1.17 2.77 0.018 2.69 1.93 3.92 <0.001 
HGF 1.58 1.04 2.36 0.022 1.17 0.84 1.65 0.372 
ICAM1 1.25 0.61 2.83 0.568 2.21 1.17 4.32 0.024 
IL-7 0.98 0.65 1.44 0.894 0.85 0.58 1.19 0.398 
IL-7R 2.38 1.60 3.58 <0.001 3.22 2.33 4.53 <0.001 
LTα 1.09 0.68 1.73 0.74 1.90 1.20 3.03 0.002 
LTβ 1.41 0.91 2.22 0.15 5.55 3.53 8.74 <0.001 
LTBR 0.76 0.48 1.19 0.25 0.79 0.50 1.21 0.296 
OPG 0.93 0.52 1.72 0.82 1.40 0.83 2.34 0.19 
PDCD1 1.36 0.53 3.58 0.520 1.91 0.87 4.07 0.124 
PDCD1LG2 1.47 0.97 2.12 0.046 2.18 1.58 3.10 <0.001 
PDPN 1.03 0.72 1.58 0.880 1.54 1.15 2.23 0.014 
SELPLG 1.80 0.93 3.90 0.104 4.43 2.48 7.78 <0.001 
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TNFRSF11A 1.09 0.54 2.57 0.838 0.31 0.15 0.59 <0.001 
TNFSF11 1.69 0.83 3.74 0.164 4.09 2.16 7.67 <0.001 
TNFSF13B 1.50 0.84 2.59 0.172 2.32 1.47 3.89 0.002 
VCAM1 1.93 1.10 3.28 0.022 2.44 1.56 3.81 <0.001 









Control 24 0 (0%) 24 
CRSsNP 53 6 (10%) 59 
CRSwNP 47 28 (37%) 75 
Total 124 34 158 
 






Neg 36 1 (3%) 37 
Pos 17 5 (23%) 22 
CRSwNP 
Neg 11 2 (15%) 13 
Pos 35 26 (43%) 61 
 
Table 2.6 Association of TLO with the number of previous operations. 
Diagnosis 
TLO: Median (IQR) Operations* 
Neg Pos 
CRSsNP 0 (1) 2.5 (2.5) 




Chapter 3: The Nasal Epithelium Mediates Tertiary 











Background: Chronic Rhinosinusitis (CRS) is characterized by persistent inflammation of the 
sinonasal mucosa. Recalcitrant CRS patients frequently present with organized ectopic 
accumulations of lymphoid cells within nasal mucosa and polyps termed Tertiary Lymphoid 
Organs (TLOs). The factors that drive TLO formation in CRS are unknown. 
Objective: To investigate the role of the nasal epithelium in mediating TLO formation in CRS. 
Methodology: Primary human nasal epithelial cells (HNECs) from 3 donors were treated with 
TLR 1-9 agonists for 48 hours and the mRNA expression of interleukin-7 receptor (IL-7R), 
lymphotoxin beta (LTB) and B-cell activating factor (BAFF) were measured by qPCR. Sinonasal 
tissue was obtained from 5 non-CRS controls, 9 CRS without nasal polyps (CRSsNP) and 14 CRS 
with nasal polyps (CRSwNP) patients and prepared into a tissue microarray (TMA) block followed 
by immunofluorescence analysis of IL-7R, LTB and BAFF. 
Results: TLR3 agonists (poly I:C) induced a significant upregulation of BAFF (fold-change=36.39, 
95% CIs=7.46, 144.02), IL-7R (fold-change=95.46, 95% CIs=13.29, 620.06) and LTB (fold-
change=37.44, 95% CIs=6.05, 253.76) after 48 hours of challenge of HNECs. LTB expression of 
submucosal cells was significantly increased in CRSsNP (p=0.032) and CRSwNP (p=0.005) 
compared to non-CRS control. IL-7R expression of submucosal cells was significantly increased 
in CRSwNP (p=0.034) compared to non-CRS control. Submucosal IL-7R expression levels 
inversely correlated with the number of eosinophils (plinear trend=0.004). 
Conclusion: The elevated expression levels of IL-7R, LTB and BAFF in HNECs in response to 
TLR3 agonists and increased influx of LTB and IL-7R expressing cells within the submucosa in 
CRSwNP patients imply that the nasal epithelium may contribute to immune cell infiltration 
involved in TLO formation. 





Chronic Rhinosinusitis (CRS) is a common chronic inflammatory condition of the paranasal sinus 
mucosa, affecting approximately 10.5% of populations in the US and Australia 3, 4. CRS accounts 
for massive healthcare costs due to its high prevalence and need for surgery9 and has a strong 
impact on the quality of life of patients. Furthermore, a conservative estimation of 10% of CRS 
patients do not respond to medical treatment and surgery, and develop refractory disease21. CRS 
patients can be phenotypically classified according to the presence or absence of nasal polyps into 
CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP)1. CRSwNP patients 
tend to have more severe disease and a higher risk of recurrence compared to CRSsNP patients18. 
We have recently found that almost 40% of CRSwNP patients present with organized ectopic 
accumulations of lymphoid cells within their nasal mucosa and polyps termed Tertiary Lymphoid 
Organs (TLOs). TLOs in the context of CRS were found in association with increased disease 
severity and with tissue eosinophilia334. TLOs are organized lymph node-like structures formed in 
response to persistent antigenic stimuli (e.g. chronic infection). TLOs possess the functions of a 
secondary lymphoid organ including the trafficking of antigen-carrying professional antigen-
presenting cells and the extravasation of circulating T and B cells, hence enhancing the generation 
of local T-cell dependent humoral immunity.  
TLOs are associated with severe chronic inflammation242, 335, and have been found in the context 
of autoimmunity, chronic infection, graft rejection and cancer164, 165, 242. The formation process of 
TLOs is complex and not clearly understood and may involve both intrinsic (e.g. autoimmunity) 
and extrinsic (e.g. chronic infection) factors. Previous studies on lymphoid neo-organogenesis have 
shown that some cell types (e.g. dendritic cells 248, 249and B cells 250) and signalling pathways (e.g. 
LTα12-LTR
250) are involved in TLO formation. However, current knowledge on TLO initiation, 
the specific cell types involved and its relation to disease progression in the context of chronic 
infections is very limited. Furthermore, current research in TLOs has been focused on immune 
cells and a potential role of epithelial cells in this process has not yet been established259. In oral 
squamous cell carcinoma, TLOs are typically located in the peritumoral stroma in close proximity 
to the epithelial layer264. Given the increasingly recognized roles of airway epithelial cells in 
mediating inflammation336 and interacting with both innate and adaptive immunity337, we 
hypothesized that epithelial cells are involved in TLO formation. This study investigates key 
factors of TLO development in ex vivo cell cultures of primary HNECs and in the context of CRS. 
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We focused on IL-7R263, 338, LTα/LTβ312, 339 and BAFF340 for their well described functions in the 
process of TLO development and maintenance.  
 
3.3 Methods 
Patients and samples 
The study was approved by The Queen Elizabeth Hospital Human Research Ethics Committee, 
Adelaide, Australia (reference number: HREC/15/TQEH/132). Informed consent was obtained 
from all donors of cells and biopsies. Control patients were patients undergoing endoscopic skull 
base procedures without clinical or radiological evidence of sinus disease. Biopsies were obtained 
from the ethmoid sinus mucosa from patients undergoing endoscopic sinus surgery for CRS at the 
Department of Otolaryngology, Head and Neck Surgery, The Queen Elizabeth Hospital, Adelaide, 
Australia. CRS patients fulfilled the diagnostic criteria set out in the position papers by the 
American Academy of Otolaryngology and Head and Neck Surgery and the European Position 
Statement (EPOS) on CRS296, 297. Patients with CRS were further sub-classified according the 
absence (CRSsNP) or presence (CRSwNP) of visible polyps present within the middle meatus on 
nasal endoscopy as defined by EPOS guidelines296, 297. Nasal polyp tissues were obtained from 
CRSwNP patients and mucosal tissues were obtained from CRSsNP and control patients. Samples 
for immunohistochemistry were washed twice in 1x PBS and fixed in 10% neutral buffered 
formalin, followed by paraffin-embedding.  
 
Cell culture 
Culturing of primary human nasal epithelial cells (HNECs) was done as described by C. Cooksley 
et al101. Briefly, the inferior turbinate was brushed using sterile nasal brushes and extracted cells 
were suspended in Bronchial Epithelial Growth Medium (BEGM, CC-3170, Lonza, Walkersville, 
MD). The cell suspension was depleted of monocytes using anti-CD68 (Dako, Glostrup, Denmark) 
coated culture dishes. HNECs were expanded in routine cell culture conditions (37 °C, humidified, 
5% CO2) in collagen-coated flasks (Thermo Fisher, Waltham, MA). Cells were seeded onto a 24-
well plate (2 cm2 per well), pre-coated overnight with 50 μg/mL human type IV collagen (C7521, 
Sigma-Aldrich, Missouri, US), at passage 1 with a cell density of 50,000 cells per well. Once cells 
reached 80% confluence, TLR 1-9 agonists (tlrl-kit1hw, Invivogen, California, USA) treatments 
were applied for 48 hours under routine cell culture conditions. BEGM without any TLR agonist 
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was used as a no treatment control. Working concentrations of all TLR agonists are listed in Table 
3.3 in the supplementary data. For immunofluorescence, primary HNECs were seeded onto Falcon 
8-chamber slides (BD, New Jersey, USA), pre-coated with collagen as described above, at 8x104 
cells/chamber, grown to 80% confluence, then treated with the TLR 3 agonist poly (I:C) for 48 




RNA was isolated from HNECs using RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was 
synthesized from RNA using Quantitect Reverse Transcription kit (Qiagen, Hilden, Germany). 
Taqman chemistry (Applied Biosystems, California, USA) was used with Biorad CFX96 
Thermocycler (Bio-rad Laboratories, California, USA) for all genes as instructed by the 
manufacturer’s protocol to perform qRT-PCR analysis to perform 45 cycles of cDNA amplification. 
Details of the Taqman probes used are listed in Supplementary Table 3.4 in the supplementary data. 
 
Histology 
Paraffin-embedded tissue samples were cut in 4µm thickness, stained with Haematoxylin & Eosin 
(H&E) and scanned using digital whole-slide imaging (WSI) technology (NanoZoomer, 
Hamamatsu). Tissue eosinophilia was determined by averaging the number of eosinophils per High 
Power Field (HPF) (0.035 mm3) from at least 6 HPF’s/slide as specified by Bassiouni et al341. The 
eosinophilia scores were determined by the average number of eosinophils per HPF as the 
following scale: 0=0-1.0; 1= 1.1-10.0, 2=10.1-20.0, 3= >20.0. The presence of TLOs was 
determined by examining the H&E-stained slides for the presence of lymphoid infiltrations as 
described by Lau et al334. 
 
Immunohistochemistry / Immunofluorescence 
Tissue handling and processing were performed as described by Cantero et al 299. In short, tissue 
cores (2mm) were prepared from formalin-fixed paraffin-embedded tissue blocks and embedded 
into the tissue microarray (TMA) block using TMA Master (3DHistech, Budapest, Hungary). 
These tissue cores were sectioned in 5µm thickness. Antigen retrieval was done at 100⁰C for 20 
minutes in pH6 sodium citrate solution. For immunofluorescence, LTB antibody (HPA048884, 
63 
Sigma-Aldrich, Missouri, USA) was used in 1:10 dilution, followed by Alexa Fluor-647 anti-rabbit 
Ab (711-606-152, Jackson ImmunoResearch Laboratory, Pennsylvania, USA) in 1:800 dilution. 
BAFF antibody (ALX-804-131-C100, Enzo Life Sciences, New York, USA) was used in 1:100 
dilution, followed by Cy3-conjugated anti-Rat Ab (112-165-075, Jackson ImmunoResearch 
Laboratory, Pennsylvania, USA) in 1:800 dilution. All primary incubations were overnight at 4⁰C 
and secondary incubations were 1 hour at room temperature. For immunohistochemistry, IL-7R 
antibody (I8409, Sigma-Aldrich, Missouri, USA) was used in 1:20 dilution and the incubation 
conditions are overnight at 4⁰C, followed by using VECTORSTAIN universal quick HRP kit 
(Vector Laboratories, California, USA) and the incubation conditions of all reagents are in 
compliance with the manufacturer’s manual. Each primary antibody has a negative staining control, 
which was incubated with non-specific antibodies raised from the corresponding host under the 
same incubation conditions. Immunofluorescence images were captured using Olympus FV3000 
confocal laser scanning microscope (Olympus, Tokyo, Japan). Immunohistochemistry images 
were taken using NanoZoomer-XR Digital slide scanner C12000-01 (Hamamatsu Photonics, 
Hamamatsu, Japan) under high resolution (40x object magnification power). For 
immunohistochemistry, protein expression levels were derived from the number of positive cells 
divided by the representative area set at 0.3 mm2. For immunofluorescence, protein expression 
levels were derived from the percentage of positively stained cells over the total number of cells, 
as determined by cell nuclei stained by 4',6-diamidino-2-phenylindole (DAPI), in a representative 
area. Image analyses were carried out by independent investigators in a double-blinded manner. 
 
Statistical analysis 
Statistical analysis for qRT-PCR was performed using R v 3.2.1342. Relative expression of qRT-
PCR data was analysed using the MCMC.qpcr library301. Briefly, Ct values were normalised to the 
β-actin gene (ΔCt), and then normalised to the no treatment control group (ΔΔCt), and 
exponentiated to report relative expression values for each treatment group. Image data analysis 
was performed using R v3.4.2 and the coin library v1.2-2343. p-values were derived by permutation 





30 patients in total were recruited to this study. 18 were male and 12 were female, aged 19 to 83. 
These patients included 6 non-CRS controls, 9 CRSsNP and 15 CRSwNP patients. 0 non-CRS 
control, 1 CRSsNP patient and 8 CRSwNP patients were TLO-positive. Demographic information 
is summarised in Table 3.2 in the supplementary data. 
 
Nasal epithelial cells express TLO genes in response to TLR agonists 
Epithelial cells were used from 3 non-CRS donors (2 females,1 male, aged 28-59). All cell donors 
were non-asthmatic and non-smokers. Gene expression was normalized to the housekeeping gene 
β-actin and to the no treatment control. TLR3 agonists (poly (I:C)) induced a significant 
upregulation of BAFF (fold-change=36.39, 95% CIs=7.46, 144.02), IL-7R (fold-change=95.46, 95% 
CIs=13.29, 620.06) and LTB (fold-change=37.44, 95% CIs=6.05, 253.76) after 48 hours of 
challenge (Figure 3.1A). BAFF was also upregulated in response to TLR2 (fold-change=6.00, 95% 
CIs=1.07, 29.32), TLR5 (fold-change=7.30, 95% CIs=1.56, 34.03), TLR7 (fold-change=6.41, 95% 
CIs=1.38, 28.59), TLR8 (fold-change=4.84, 95%CIs=1.14, 20.91) and TLR9 agonists (fold-
change=7.86, 95% CIs=1.67, 32.97). Protein expression of IL-7R, LTB and BAFF induced by poly 







Figure 3.1 Expression of TLO-related genes/proteins in primary nasal epithelial cells in 
response to TLR agonists treatment. 
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A) The mRNA expression of IL-7R, LTB and BAFF in response to TLR 1-9 agonist treatment for 
48 hours, normalized to the housekeeping gene and to the no-treatment control. *p<0.05, **p<0.01, 
***p<0.001 B) Poly (I:C) induces IL-7R, BAFF and LTB protein expression as shown by 
immunofluorescence. 
 
Expression of TLO genes by immunohistochemical analysis 
The p-values in this section were derived from Kruskal-Wallis tests unless otherwise specified. IL-
7R was expressed in epithelium and submucosal immune cells (Figure 3.2) and was significantly 
higher in submucosal cells in CRSwNP compared to control (p=0.034) (Figure 3.3A). IL-7R was 
lower in asthmatic CRS patients versus non-asthmatic CRS patients, however, this was not 
statistically significant (p=0.076) (Figure 3.3D). IL-7R protein expression in submucosal cells in 
CRS inversely correlated with tissue eosinophilia score (p=0.012) by linear-by-linear association 
test (Figure 3.3F). LTB was also expressed in the epithelium with stronger expression in immune 
cells within the submucosa (Figure 3.4). Submucosal LTB expression was significantly increased 
in both CRSsNP and CRSwNP patients compared to non-CRS controls (poverall=0.013) (Figure 
3.3B). Epithelial IL-7R and BAFF expression was variable between different patient tissues and 
appeared to be higher in CRSwNP but the difference did not reach statistical significance (IL-7R, 
p=0.201, BAFF, p=0.07) (Figure 3.5). There was no significant difference in BAFF expression by 
diagnosis in submucosal cells. There was no significant difference in the epithelial or submucosal 
expression of IL-7R, LTB and BAFF by TLO phenotype in CRS patients. Details of expression 
levels of IL-7R, LTB and BAFF in epithelial cells and submucosal cells are listed in Table 3.1. 
Clinical/demographical associations 
IL-7R, LTB or BAFF expression neither differs by gender by Kruskal-Wallis test nor correlates 
with age or the number of previous operations by linear regression. 
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Table 3.1 Expression of IL-7R, LTB and BAFF in epithelial cells and submucosal cells. 
Epithelial cells  Submucosal cells 




(cells/mm2) SD P-val N Diagnosis 
Mean 
expression 
(cells/mm2) SD P-val N 
Control 110.2 140.0  4 Control 90.8 74.3  4 
CRSsNP 242.1 250.6 0.481 8 CRSsNP 485.2 494.9 0.126 8 
CRSwNP 270.8 243.8 0.202 14 CRSwNP 432.2 655.9 0.034* 14 
Total 
  















(cell count) SD P-val N Diagnosis 
Mean 
expression 
(cell count) SD P-val 
                 
N 
Control 28.6 18.2  6 Control 4.4 7.5  6 
CRSsNP 29.4 11.2 0.831 9 CRSsNP 36.8 29.5 0.032* 9 
CRSwNP 32.9 14.9 0.904 15 CRSwNP 58.0 26.3 0.005* 15 
Total 
  











(cell count) SD P-val N Diagnosis 
Mean 
expression 
(cell count) SD P-val N 
Control 1.5 1.3  6 Control 17.9 23.4  6 
CRSsNP 6.0 7.7 0.172 9 CRSsNP 16.9 13.9 0.806 9 
CRSwNP 7.9 8.6 0.077 15 CRSwNP 25.0 14.8 0.360 15 
Total 
  







Figure 3.2 Representative images of IL-7R expression in a CRSwNP patient. 
(A) The red arrow indicates IL-7R expressing epithelial cells and the blue arrow indicates IL-7R 
expressing submucosal cells. (B) Negative stain control 
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Figure 3.3 Protein expression in submucosal cells. 
A-C) IL-7R, LTB and BAFF by patient groups respectively. D) Submucosal IL-7R expression in 
relation to asthma E) LTB expression in CRS patients by TLO status. F) Submucosal IL-7R 
expression in relation with tissue eosinophilia score *p<0.05, **p<0.01, ***P<0.001 
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Figure 3.4 A representative image of LTB expression in a CRSwNP patient. 
(A) The yellow arrow indicates LTB expressing epithelial cells and the white arrow indicates LTB 
expressing submucosal cells. (B) Negative stain control. 
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TLOs have been a hot-spot for research in recent years due to their contributions to chronic 
inflammation, especially in autoimmune diseases164, 165, 175. We have recently demonstrated the 
presence of TLOs in nasal polyps and its associations with tissue eosinophilia and disease 
recalcitrance represented by the number of previous operations334. It has been shown that nasal 
polyp TLOs locally produced IgG, IgA and IgE but not IgM344. This indicates the existence of an 
antigen-specific B-cell response that might drive chronic inflammation in these patients, supporting 
the hypothetic role of TLOs in promoting pathogenic inflammation in CRS. Our data provides 
evidence supporting the notion that nasal epithelial cells might be involved in TLO development. 
Our gene expression analysis has shown that HNECs strongly express genes important for TLO 
induction, namely IL-7R, LTB and BAFF, in response to Poly (I:C) for 48 hours. This finding 
suggests that HNECs are equipped with some of the genes that are required for TLO induction with 
activation occurring upon prolonged TLR3 activation. The TLR3 agonist Poly (I:C) is a synthetic 
analogue of dsRNA and mimics viral infection and replication. The TLR3 protein is constitutively 
expressed at high levels in epithelial cells 345 and HNECs have been shown to respond vigorously 
to TLR3 agonists101 . Whether RNA viruses, such as Rhinovirus or influenza virus which are 
frequently found in mucosal washes of CRS patients 346, play a role in TLO initiation in the context 
of CRS warrants further investigation. Interestingly, influenza virus lung infections have been 
shown to induce TLO formation241.  
There has been a rising interest in epithelial cells for their ability to mediate immune responses219. 
Epithelial cells are well recognized as an integral part of the innate immunity125, 128, 336, 347. Their 
role in mediating adaptive immunity has recently been identified 219, 337, especially in the context 
of B-cell responses295 which are particularly relevant to TLO functions. Using 
immunofluorescence, our study confirmed the expression of LTB, IL-7R and BAFF within the 
epithelial layer of the sinonasal mucosa. However, whilst the epithelium-specific expression of 
BAFF and IL-7R appeared increased in CRSwNP compared to control in some patients, these 
differences did not reach statistical significance in this study population. A larger study involving 
more samples is needed to fully elucidate the differential expression patterns of BAFF and IL-7R 
within the epithelium of CRS patients and controls.  
Apart from the epithelium-specific expression, LTB and IL-7R expression was also identified in 
cells within the submucosa in close proximity to the epithelium and was significantly increased in 
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CRS patient tissues compared to controls. Interestingly, in the context of oral mucosal cancers, 
TLOs are typically found close to the tumor margin within the lymphocyte-rich subepithelial 
areas264. Given the crucial functions of IL7-IL-7R and LTα1β2-LTBR engagement in early 
lymphoid organ development and the increased expression of these genes both within the 
epithelium upon stimulation with TLR agonists and in immune cells located in the immediate 
vicinity of the epithelium, these findings suggest that the epithelium plays a central role in the TLO 
induction/maintenance process. In view of our findings of significantly increased expression of 
these proteins within the submucosa rather than in the epithelium layer itself indicates that HNECs 
could play a role in attracting immune cells expressing TLO initiation signals rather than being the 
major source of these signals. 
The inverse correlation of submucosal IL-7R expression with tissue eosinophilia is intriguing and 
its mechanism and significance unclear. IL-7R has a critical role in immune cell development and 
homeostasis, and mutations in this gene are associated with the pathogenesis of severe combined 
immunodeficiency (SCID). IL-7R (alias CD127) is a receptor for both IL-7 and for thymic stromal-
derived lymphopoietin (TSLP) and has a role in T- and B-cell development and homeostasis (via 
IL-7) and allergic responses and Th2 inflammation (via TSLP)348. The regulation of IL-7R 
expression is complex and it has been reported that IL-7 can downregulate IL-7R protein 
expression and induces the shedding of IL-7R from CD8+ T cells349. Also, the presence of a 
persistent antigen can suppress IL-7R expression and this correlates with T cell exhaustion350 and 
immune dysfunction. IL-7R is expressed on eosinophils and IL-7R Single Nucleotide 
Polymorphisms have been shown to confer susceptibility to mite-sensitized asthma351. Further 
research is needed to shed light on IL-7R protein expression and its relation to IL-7 and TSLP 
protein levels, tissue eosinophilia and immune dysfunction in the context of CRS. 
 
3.6 Conclusion 
Our study has indicated the capability of nasal epithelial cells to play a potential role in TLO 
development. Further comprehensive studies are needed to investigate the triggers and molecular 
and cellular pathways of TLO formation in the context of CRS. 
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3.7 Supplementary data 
Table 3.2 Summary of patient demographics 
 
Control CRSsNP CRSwNP 
Number 6 9 15 
Age (IQR) 51 (47 - 56) 48 (26 - 56) 57 (43 - 62) 
Male/Female 1/5 6/3 11/4 
Asthma/non-
asthma 
1/5 3/6 6/9 
TLO/non-TLO 0/6 1/8 8/7 
Average previous 
ESS 




Table 3.3 Working Concentration of TLR 1-9 agonist treatment 
Agonist of  Agonist name Working concentration 
TLR 1 Pam3CSK4  1 μg/ml 
TLR 2 HKLM  108 cells/ml 
TLR 3 Poly(I:C) High molecular weight * 10 μg/ml 
TLR 3 Poly(I:C) Low molecular weight * 10 μg/ml 
TLR 4 LPS 1 μg/mL 
TLR 5 Flagellin  1 μg/ml  
TLR 6 FSL-1 1 μg/ml 
TLR 7 Imiquimod   1 μg/ml 
TLR 8 ssRNA40 1 μg/ml 
TLR 9 ODN2006 5 μM  
* All results in this study from Poly(I:C) HMW and LMW were very close. The reported numbers 
are the average of the two. 
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Table 3.4 Details of Taqman probes 
AssayID Gene 







Chapter 4: Reduced Serum Immunoglobulin G Levels in 













Background: Organized ectopic accumulations of lymphoid cells, termed Tertiary Lymphoid 
Organs (TLOs), are frequently found in Chronic Rhinosinusitis with nasal polyps (CRSwNP) 
patients. TLOs are formed in response to persistent antigen stimulation and are thought to serve 
mainly local humoral immune responses. Matched systemic and local humoral immunity and the 
presence of Anti-Nuclear Antibodies (ANAs) in relation to TLO status have not been studied in 
the context of CRS.  
Objective: To investigate the relationship of TLO status with serum and tissue immunoglobulin G 
(IgG) levels, and the presence of ANAs in CRS. 
Methods: Sinonasal tissue and serum was obtained from 12 non-CRS controls, 18 CRS without 
nasal polyp (CRSsNP) patients and 34 CRSwNP patients. Haematoxylin & Eosin (H&E)-stained 
tissue sections were analysed for the presence of TLOs. Tissue lysates and sera were analysed for 
IgG levels by ELISA. The presence of ANAs against 12 autoantigens in sera and tissue lysates was 
determined by immunoblot assays. 
Results: TLO+ CRSwNP patients had significantly reduced serum IgG levels compared to TLO-
CRSwNP patients (p=0.044). Nasal polyp IgG levels were significantly increased compared to 
CRSsNP (p=0.0005) and non-CRS control mucosa (p<0.0001). Nasal polyp IgG levels did not 
differ by TLO status (p=0.46). No systemic ANAs were detected in any subjects tested. 
Conclusion: CRSwNP patients with TLOs have lower serum IgG levels than their TLO-negative 
counterparts. No detectable ANAs were found in any subjects tested. 
 
4.2 Introduction 
Chronic Rhinosinusitis (CRS) is characterized by the persistent inflammation of the 
paranasal sinus mucosa. CRS is phenotypically classified into CRS with nasal polyps (CRSwNP) 
or CRS without nasal polyps (CRSsNP) based on the endoscopic evidence of the presence of nasal 
polyps in the middle meatus1. These two sub-classes of CRS possess different clinical and 
morphological characteristics with CRSsNP frequently presenting with a Th1-type inflammation 
and CRSwNP often having a predominant Th2-type of inflammation with increased expression of 
Th2 cytokines (such as IL-5 and IL-13), tissue eosinophilia and goblet cell hyperplasia 1, 18, 73, 352.  
 Our recent research highlights the presence of organized ectopic accumulations of 
lymphoid cells, termed tertiary lymphoid organs (TLOs), in up to 28% of CRSwNP patients and 
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the associations of TLOs with recalcitrant CRS and tissue eosinophilia334. TLOs form in tissues 
affected by severe chronic inflammation and can be protective (e.g. in the context of cancer) or 
detrimental to the disease process (e.g. in transplant rejection and autoimmune diseases) 164, 165, 175, 
242. We have shown that the expression of many genes related to chronic inflammation and TLOs 
is increased in nasal polyps of CRSwNP patients compared to the nasal mucosa of CRSsNP patients 
and control subjects. These genes include key players of TLO formation and function such as 
lymphotoxin alpha (LTA) and lymphotoxin beta (LTB) and genes critical for immunoglobulin 
class switching such as Activation Induced Cytidine Deaminase (AICDA) and B-cell Activating 
Factor of the TNF Family (BAFF) 334. BAFF, a B-cell survival factor, is a therapeutic target in 
systemic autoimmune diseases353, which are associated with both TLOs and anti-nuclear 
autoantibodies (ANAs). 
Multiple reports have shown that there is an increased local class-switched immunoglobulin 
production in nasal polyps78, 212, 216, 217, indicating an increased antigen-specific humoral immune 
response within nasal polyps354. In contrast, whereas up to 17.9% of CRS patients show humoral 
immune dysfunction with low serum IgG levels (reviewed in Berger et al355), average serum IgG 
levels were found to be similar in CRS versus non-CRS patients in different studies350, 356. 
Furthermore, Tan et al had demonstrated increased levels of anti-dsDNA IgG and IgA within nasal 
polyps of CRSwNP patients, indicating the presence of local ANAs within nasal polyp tissue291. 
Anti-dsDNA is an ANA specificity that is characteristic of a subset of patients with Systemic Lupus 
Erythematosus (SLE)357. Since TLOs can be the local production site of ANAs271, 293, we 
hypothesised that an autoimmune component contributes to the persistent inflammation in 
CRSwNP patients with TLOs. Although TLOs have been identified in nasal polyps and found to 
be associated with CRS disease recalcitrance 334 and increased levels of local immunoglobulins344, 
the link between TLOs, local and systemic IgG levels and ANAs has yet to be determined. In this 
study, we used matched serum and nasal tissue samples from CRS patients and non-CRS controls 
and assessed IgG and ANA levels in relation to the TLO status and disease severity scores. 
 
4.3 Methods 
Patients and samples 
This study was approved by the Human Research Ethics Committee of The Queen Elizabeth 
Hospital, Adelaide, Australia (reference number: HREC/15/TQEH/132). Biopsies were obtained 
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from the ethmoid sinuses from patients undergoing endoscopic sinus surgery for CRS at the 
Department of Otolaryngology, Head and Neck Surgery, The Queen Elizabeth Hospital, Adelaide, 
Australia. Control patients were patients undergoing endoscopic skull base procedures without 
clinical or radiological evidence of sinus disease. CRS patients fulfilled the diagnostic criteria set 
out in the recent position papers by the American Academy of Otolaryngology and Head and Neck 
Surgery and the European Position Statement (EPOS) on CRS 296, 297. Patients with CRS were 
further sub-classified according to the absence (CRSsNP) or presence (CRSwNP) of visible polyps 
present within the middle meatus on nasal endoscopy as defined by EPOS guidelines 296, 297. Nasal 
polyp and non-polyp mucosa tissues were obtained from CRSwNP patients and mucosal tissues 
were obtained from CRSsNP and control patients. 
Preparation of protein extract from tissues 
Freshly obtained nasal polyps and turbinate tissues were snap-frozen and stored at -80oC until 
needed. Tissues were thawed on ice. Approximately 100mg of tissue was suspended in 1mL of T-
per tissue protein extraction buffer (product no. 78510, Thermo Fisher Scientific, MA, US) 
containing 1% v/v HALT protease inhibitor cocktail (product no. 87786, Thermo Fisher Scientific, 
MA, US). The samples were then homogenized with Qiagen Tissuelyser (product no. 85220, 
Qiagen, Hilden, Germany) at 30 hertz for 20 minutes. The homogenized suspensions were 
centrifuged at 17,000g for 10 minutes at 4OC and the supernatants were stored at -80 OC until 
analysis. The protein concentrations of tissue extracts were determined using the Pierce BCA 
Protein Assay Kit (product no. 23225, Thermo Fisher Scientific, MA, US).  
Measurement of serum and tissue IgG levels by ELISA 
IgG levels were measured by using the total IgG ELISA kit (catalogue no. 88-50550-88, Thermo 
Fisher Scientific, MA, USA) as per the instructions by the manufacturer. The detection range of 
this ELISA is 1.5-100 ng/mL. Tissue lysate samples were diluted to 1 μg of total protein per mL 
and serum samples were diluted 100,000 folds. Hence, all tissue lysate IgG levels are reported in 
ng of IgG per μg of total protein. 
Detection of autoantibodies 
The presence of autoantibodies against 12 ANA-associated autoantigens (nRNP, Sm, SS-A (SS-A 
native and Ro-52), SS-B, Scl-70, Jo-1, CENP B, dsDNA, Nucleosomes, Histones and ribosomal 
P-Protein) were tested by Euroimmun ANA Profile I Immunoblot kits (catalogue no. DL 1590-
6401-8G, Euroimmun, Lübeck, Germany). The tests were performed as per the manufacturer’s 
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manual. For serum samples the standard protocol was used. For tissue lysate samples, 400 μL was 
used per sample and the primary incubation step was extended to 3 hours instead of 30 minutes. 
The blots were evaluated by the EUROLineScan (Euroimmun, Lübeck, Germany) for scanning 
and analysis. Background cut-off value was ≤10 intensity unit. 3 serum samples known to possess 
ANAs were used as positive controls. 
Histology 
Paraffin-embedded tissue samples were cut in 4µm thickness, stained with Haematoxylin & Eosin 
(H&E) and scanned using digital whole-slide imaging (WSI) technology (NanoZoomer, 
Hamamatsu). Tissue eosinophilia was determined by averaging the number of eosinophils per High 
Power Field (HPF) (0.035 mm3) from at least 6 HPF’s/slide as specified by Ramezanpour et al 298. 
TLO status was determined by examining H&E-stained histology as described by Lau et al334. 
Statistical analysis 
Gamma (log link) regression (coefficients were exponentiated and have interpretation as the ratio 
of IgG levels, relative to the base (reference level)) was performed using Stata v15.1 (StataCorp 
LLC, Texas, USA). Krusal Wallis test with Benjamini-Hochberg post-hoc correction was 





64 patients were involved in this study including 12 non-CRS controls, 18 CRSsNP patients and 
34 CRSwNP patients. These patients were aged between 23 and 76 years old with 27 females and 
37 males. 0/12 non-CRS control, 1/18 CRSsNP and 9/34 CRSwNP patients were positive for TLOs. 
Demographical and clinical information of all patients is listed in Table 4.4 in the supplementary 
data. 
Serum IgG levels are decreased in TLO-positive CRS patients 
Within CRSwNP patients, the presence of TLOs was correlated with significantly lower serum IgG 
levels adjusted for gender (padjusted=0.044) (Figure 4.1A). There was no significant difference in 
serum IgG levels when comparing CRS versus control (padjusted=0.28) or CRSsNP versus CRSwNP 
(padjusted=0.27) (Figure 4.1B). Serum IgG analysis is summarized in Table 4.1. Within CRS patients, 
there were no correlations between serum IgG and asthma (p = 0.23), eosinophilia score (plinear = 
0.34) nor number of previous operations (plinear = 0.73) (data not shown). 
85 
 
Figure 4.1 Serum IgG levels within CRSwNP patients 
Serum IgG levels by TLO (A) and patient groups (B). 
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Table 4.1 Serum IgG analysis 
(A) Serum IgG levels (mg/mL) by patient groups: 
 
Group N Median IQR 
Control 12 0.980 0.911 
CRSsNP 18 1.604 1.078 
CRSwNP:TLO neg 20 1.315 1.422 
CRSwNP:TLO pos 9 0.815 0.449 
Total 59 1.152 1.209 
 
(B) Serum IgG regression analysis estimates adjusted for gender: 
Group IgG Ratio Lower CI Upper CI p-value 
Controls 1 (base) 
   
CRSsNP 1.37 0.91 2.08 0.13 
CRSwNP:TLO neg 1.33 0.86 2.04 0.20 
CRSwNP:TLO pos 0.81 0.50 1.32 0.40 
Females 1 (base) 
   
Males 1.30 0.95 1.78 0.10 
 
        (C) Serum IgG Helmert contrasts: 
Helmert Contrast 
Unadjusted Adjusted for Gender 
df chi2 p-val df chi2 p-val 
Controls vs CRS 1 3.21 0.073 1 1.18 0.28 
CRSsNP vs CRSwNP 1 1.03 0.31 1 1.23 0.27 
CRSwNP: TLO neg vs CRSwNP: TLO pos 1 4.39 0.036 1 4.04 0.044 
 
Local IgG levels are elevated in CRSwNP patients versus CRSsNP patients and non-CRS 
controls 
IgG levels in CRSwNP mucosal tissue were significantly higher than in non-CRS control 
(padjusted=0.021) (Figure 4.2A). Mucosal IgG levels in CRSwNP were also higher than CRSsNP but 
this did not reach statistical significance (padjusted=0.060) (Figure 4.2A). Nasal polyp IgG levels 
were significantly increased compared to CRSsNP (p=0.0005) and non-CRS control mucosa 
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(p<0.0001) (Figure 4.2A). Within CRSwNP, nasal polyp IgG levels appeared to be higher than that 
of mucosa, but this did not reach statistical significance (p=0.059) (Figure 4.2A). Nasal polyp IgG 
levels did not differ by TLO status (p=0.46) (Figure 4.2B). Tissue IgG levels in CRSwNP and 
mucosal IgG analysis is summarized in Table 4.2 and Tables 4.3 respectively. 
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Figure 4.2 Tissue IgG levels 
Tissue IgG levels by patient groups and tissue type (A); IgG levels in nasal polyps by TLO status 
(B). *p<0.05, **p<0.01, ***p<0.001 
89 
Table 4.2 Tissue IgG level in CRSwNP 
(A) Polyp versus mucosa IgG levels (left) and polyp IgG levels by TLO status (right): 
 
Group N Median IQR Group N Median IQR 
Mucosa:CRSwNP  17 22.75 8.79 Polyp:TLO neg 17 29.3 22.9 
Polyp:CRSwNP 27 30.85 16.98 Polyp:TLO pos 8 31.9 18.5 
Total 44 53.60 25.77 Total 25 30.5 17.8 
(B) Polyp IgG regression analysis estimates: 
Unadjusted (n = 25) 
Group IgG Ratio Lower CI Upper CI p-value 
CRSwNP:TLO neg 1 (base) 
   
CRSwNP:TLO pos 1.16 0.78 1.74 0.46 
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Table 4.3 Mucosal IgG analysis 
(A) Mucosal IgG (ng/μg of total protein) by group: 
 
Group N Median IQR 
Control 12 15.0 6.9 
CRSsNP 17 18.4 5.9 
CRSwNP 17 22.8 8.8 
Total 46 18.3 8.2 
(B) Mucosa IgG regression analysis estimates: 


















Control 1 (base) 
   
Controls 1 (base) 
   
CRSsNP 1.20 0.94 1.55 0.15 CRSsNP 1.19 0.91 1.54 0.20 
CRSwNP 1.57 1.15 2.15 0.004 CRSwNP 1.55 1.15 2.10 0.004 
     
Females 1 (base) 
   
          Males 1.04 0.83 1.30 0.74 
(C) Mucosa IgG Helmert contrasts: 
Helmert Contrast 
Unadjusted Adjusted for Gender 
df chi2 p-val df chi2 p-val 
Controls vs CRS 1 6.43 0.011 1 5.99 0.014 
CRSsNP vs CRSwNP 1 3.69 0.055 1 3.53 0.060 
Joint 2 8.24 0.016 2 8.24 0.016 
 
Assessing the presence of autoantibodies against 12 autoantigens by immunoblot 
The presence of antibodies to 12 autoantigens was tested in serum and tissue. All 3 positive controls 
were positive for at least one autoantibody. No autoantibodies were detected in the sera of any of 
the 64 patients. Autoantibodies were detected in the tissue lysates of 0/8 TLO-positive nasal polyps. 
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4.5 Discussion 
This is the first study demonstrating reduced serum IgG levels in CRSwNP patients presenting with 
TLOs compared to CRSwNP patients without TLOs. The significance of this finding, and in 
particular the relationship of low serum IgG with TLOs is unclear and warrants further 
investigation. Whilst it is thought that the contribution of TLOs to adaptive immunity serves mainly 
local immune responses to a persistent antigen, previous studies have shown positive correlations 
between serum IgG levels and Germinal Centre (GC)-positive immune infiltrations in the context 
of Sjögren’s Syndrome358. Furthermore, studies in mice have shown inducible bronchus-associated 
lymphoid tissue (iBALT), a form of TLO induced in the lungs after influenza virus infection, 
contributes significantly to systemic humoral immunity in a process that is dependent on dendritic 
cell function359. In contrast to our finding of a reduction of serum IgG levels, these studies indicate 
increased serum IgG levels in relation to TLO formation. Reduced circulating total IgG levels have 
been associated with recurrent respiratory tract infections360. In a recent study involving more than 
1600 samples, serum IgG levels, in a dose-dependent manner, were significantly and independently 
related to Chronic Obstructive Pulmonary Disease (COPD) exacerbations and hospitalizations361. 
A number of studies have shown humoral immune dysfunction with low serum IgG levels in 9-
17.9% of CRS patients (reviewed in Berger et al355). In a systematic review and meta-analysis 
involving >1400 CRS patients, immunoglobulin deficiencies were identified in 12.7% of patients 
with recurrent CRS (defined as CRS patients not controlled by appropriate conservative 
management for 4 months) and in 22.8% of patients with difficult-to-treat CRS (defined as non-
controllable rhinosinusitis despite successful sinus surgery and appropriate conservative 
management for at least 1 year)362. In contrast, less than 1% of the general population are estimated 
to have immunoglobulin deficiencies363, 364. In view of these findings of a greater than 10-fold 
higher prevalence of immunoglobulin deficiencies in patients with recurrent CRS, our finding of 
an increased prevalence of TLOs in recalcitrant CRS patients334 and the association of TLO 
positivity with reduced serum IgG levels, it is tempting to speculate that TLO+ CRS patients might 
represent a distinct CRS endotype characterised by low serum IgG levels. The exact nature and 
cause of reduced IgG levels and whether, apart from IgG, also other immunoglobulins or IgG 
subtypes are involved is unknown and warrants further investigation. Interestingly, specific 
pathogens have been shown to ablate B cell responses by suppressing the expression of 
transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) and/or B 
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cell-activating factor of the tumor necrosis factor family-receptor (BAFF-R) on B cells365. Together 
with BAFF and A Proliferation-Inducing Ligand (APRIL), these “BAFF system molecules” play 
critical roles in antibody responses to microbial infections. The downregulation of TACI and/or 
BAFF-R by specific pathogens is regarded as a potent virulence mechanism rendering the immune 
response to these pathogens ineffective and resulting in reduced systemic immunoglobulin levels366. 
Further studies are required to elucidate the identity of the microbiome in associated with TLO 
formation in CRSwNP patients and how this relates to markers of B-cell specific immune activation 
and function.  
The finding of reduced systemic IgG levels is important since for symptomatic immunoglobulin 
deficiencies, early antibiotic treatment and preventive intravenous or subcutaneous 
immunoglobulin substitution therapy could help alleviate the chronic inflammation and infection367, 
368. Restoring normal serum IgG has shown to be beneficial, improving lung function and reducing 
acute exacerbations for patients who present with asthma or COPD and are found to have 
underlying antibody deficiency 369. 
In terms of local IgG levels, nasal polyps contained elevated IgG compared to the mucosa of 
CRSsNP patients and non-CRS controls as reported by other groups291, 370. Despite the previous 
report of elevated IgG levels in nasal polyps with TLOs compared their TLO-negative 
counterpart344, there was no significant difference in nasal polyp IgG levels by TLO status in our 
study population. It is clear that various immune cells, including antibody-secreting plasma cells 
and other B cells, are enriched in nasal polyps161, 356, 370, 371, indicating that germinal centres in 
TLOs are not the sole contributors to the IgG levels. Perhaps the selection of more mature TLOs 
(or high grade TLO as described by Song et al344) is needed to demonstrate TLO-driven IgG 
production versus a plasma-cell-rich nasal polyp without TLOs.  
Tan et al. used ELISA assays to show elevated local anti-dsDNA IgG and IgA levels in nasal polyps 
compared to CRSsNP and control mucosa, which, when detected in serum, are markers for 
autoimmune diseases such as SLE291, 357. To test the hypothesis that TLOs in the context of CRS 
are associated with increased production of auto-antibodies, we tested the presence of systemic and 
local IgG against 12 autoantigens, using immunoblot assays, which are routinely used in the 
standard diagnostics of auto-immune diseases 372. There were no significant ANA levels detected 
in any of the 64 tested sera, indicating that none of the CRS patients tested had evidence of auto-
immunity. In addition, no ANAs were detected in any of the TLO-positive nasal polyp lysate 
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samples. Since the levels of IgG in tissue lysates are much lower than that of sera as shown in our 
ELISA results, the ANA levels in our tissue lysates might not fall under the detection range of the 
immunoblot assay. There are flaws in detecting ANAs using ELISA373, 374 and validations are 
needed before the its results can be properly interpreted. Interpretations of anti-dsDNA ELISA 
results in previous studies were based on simple variation in absorbances, which were not validated 
against positive and negative samples. On the contrary, the immunoblot assay has a good agreement 
with gold-standard technique for the detection of ANAs375, 376 and can test multiple ANAs per run. 
Therefore, we chose the immunoblot assay in our study and the choice of methods must be carefully 
considered in future ANA research.  
 
4.6 Conclusion 
In conclusion, this study has demonstrated that CRSwNP patients with TLOs have lower serum 
IgG levels than their TLO-negative counterparts. Future studies are required to determine the 
significance and pathophysiology of this finding. 
 
4.7 Supplementary data 
Table 4.4 Summary of patient demographics 
 
Control CRSsNP CRSwNP 
Number 12 18 34 
Age (IQR) 56 (41 - 61) 58.5 (48 - 66) 57 (45 - 67) 
Male/Female 3/9 12/6 22/12 
Asthma/non-asthma 0/12 3/15 14/20 
TLO/non-TLO 0/12 1/16 9/21 
Average previous ESS NA 1.11 1.38 
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Chapter 5: Discussion 
CRS is a multifactorial disease characterized by the persistent inflammation of the sinonasal 
mucosa with a high degree of heterogeneity between patients. According to the widely accepted 
criteria proposed by the European Position Statement (EPOS), CRS is classified into CRSsNP and 
CRSwNP based on the absence or presence of endoscopically visualised nasal polyps in the middle 
meatus1. This classification has been widely adopted and useful in the clinical setting as it proposes 
treatment strategies adapted to these CRS phenotypes73. CRSwNP is characterised by eosinophilic 
inflammation and Th2- type immune responses 
73, and is usually responsive to steroid treatment as 
manifested by reduced eosinophil activation377 and reduced polyp size378, 379. In contrast, CRSsNP 
is frequently characterized by a Th1-type of inflammation and is usually treated with topical 
steroid1. However, more advanced methods of CRS patient classification have emerged recently, 
such as the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis 
(JESREC) study178 which sub-divided CRSwNP patients by the degree of eosinophilic 
inflammation. These different classification systems reflect the high levels of heterogeneity in CRS 
phenotypes and perhaps the classification of CRS sub-types based solely on nasal polyps is an over 
simplification. For example, it does not take into account the wide spectrum of immunological 
disease profiles, such as the involvement of the ectopic aggregation of lymphoid cells217 and 
different immunoglobulin isotypes216, 370, underlying the persistent inflammation in CRS. 
Organized structures of lymphoid cells called TLOs have been found in many severe chronic 
inflammatory conditions including autoimmune diseases, chronic infection, organ transplant 
rejection and cancer164, 165, 242. We hypothesized that TLOs are present in CRS and contribute to its 
persistent inflammation. To investigate this, we examined tissue from CRSsNP and CRSwNP for 
the expression of genes related to TLO formation and functions, and the presence of 
histopathological structures that resemble TLOs. 
Our results showed that many genes important for TLO formation and maintenance were 
upregulated in CRS, mainly in CRSwNP. Hierarchical clustering analysis of the expression pattern 
of these TLO-related genes showed a cluster of genes that are crucial for TLO formation and GC 
reactions tended to co-express in the same patients, indicating that TLO-mediated pathology drives 
the inflammation in a distinct subset of CRS patients. We also confirmed that the aberrant lymphoid 
cell aggregates found in the nasal polyps were in fact TLOs by demonstrating the presence of FDCs, 
HEVs and B/T cell zones, and the lymphoid-follicle-specific spatial organization between them. 
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We examined the histology of 158 patients and found that TLOs were present in 37% of CRSwNP 
patients, 10% of CRSsNP patients and none of non-CRS controls, demonstrating that TLOs were 
exclusive to CRS and were more prevalent in CRSwNP versus CRSsNP. Correlation of clinical 
and demographical information with the presence of TLOs was then evaluated. We showed that 
tissue eosinophilia and the number of previous operations were associated with TLOs, suggesting 
that TLOs contribute to severe inflammation and the development of recalcitrant disease in 
CRSwNP. The discovery of the presence of TLOs in CRS adds to the understanding of the 
pathophysiology of refractory CRS. The discovery may pave the way for the discovery and 
development of new non-steroid treatments for recalcitrant CRS such as biologics blocking TLO 
pathways380. 
With the knowledge of the significance of TLOs in CRS, we next investigated the role of the nasal 
epithelium in mediating TLOs and its interactions with other aspects of CRS immunology. Airway 
epithelial cells substantially contribute to Th2-type responses
162, making them highly relevant in 
driving the chronic inflammation in CRSwNP336. Our study found an increased expression of three 
genes that are crucial for TLO formation, namely IL-7R, LTB and BAFF, in primary HNECs in 
response to TLR 3 agonist (poly (I:C)) treatment by both qPCR and immunofluorescence, 
demonstrating that HNECs are capable of facilitating TLO development and this supports the 
hypothetical role of HNECs in TLO formation. We next examined the expression of these three 
proteins in the epithelium and the adjacent submucosal cells using patient-derived tissue 
microarrays. Our results showed that submucosal LTB and IL-7R were upregulated in CRS patients 
compared to non-CRS controls. Given the importance of IL7-IL-7R and LTα1β2-LTBR 
engagement in early lymphoid organ development, the increased expression of IL-7R and LTB in 
the immune cells in close proximity to the nasal epithelium and in the epithelial cells upon 
stimulation by TLR agonists suggests that the epithelium is central to the TLO 
formation/maintenance process. Previous studies had demonstrated the ability of epithelial cells to 
recruit B cells to the subepithelial area381, 382 and directly mediate immunoglobulin class-
switching295. Our findings of elevated expression of LTB and IL-7R in the submucosa rather than 
in the epithelium layer itself also supports the notion that the epithelium could facilitate TLO 
formation by attracting immune cells carrying TLO initiation signals, such as LTi cells, to the 
submucosa. 
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Intriguingly, there were inverse correlations of submucosal IL-7R expression with both tissue 
eosinophilia and asthma, but the mechanism and significance of this finding is unclear. Apart from 
its importance in hematopoietic cell development383, 384, 385, IL-7R is expressed by many immune 
cell types, especially during activation in the peripheral tissue including DCs386, monocytes387, 
CD4+ T cells386, LTi cells170 and eosinophils351, and its immune functions and regulation are 
complex338. The IL-7 signalling is required in a defined time-frame during early Peyer’s patch 
development388, 389. Given the resemblance of the process of SLO and TLO neo-organogenesis, 
strong submucosal expression of IL-7R could represent an early stage in TLO development and 
inflammatory stage that is distinctive from the well-developed eosinophilic/asthmatic 
inflammation. 
Few studies have investigated the local and systemic immunity in matching samples in the context 
of CRS, and their relationships with the presence of TLOs. Our study is the first to demonstrate 
lowered serum IgG levels in CRS patients with TLOs compared to CRS patients without TLOs. 
Traditionally, TLOs are thought to have enhancing effects on humoral immunity mainly on a local 
level. Some studies have shown positive correlations of serum IgG levels and TLOs as in Sjögren’s 
Syndrome358 and a murine model of influenza virus-induced TLOs241. The discordant relationship 
of TLOs and reduced serum IgG in the context of CRS warrants further investigations. Interestingly, 
low immunoglobulin levels are not uncommon in respiratory diseases. Reduced IgG2 and IgA 
levels were observed in recurrent respiratory tract infections390, and lower serum IgG levels were 
associated with worse disease outcomes in COPD361. Furthermore, there was more than a 10-fold 
increase of the prevalence of immunoglobulin deficiencies in recurrent CRS patients than in the 
general population362, 363, 364. It is speculated that immunoglobulin deficiency is associated with a 
distinct CRS endotype that is represented by CRS patients with TLOs. Most importantly, these 
findings may have profound therapeutic implications as preventive treatments have been shown to 
help alleviate the chronic inflammation and infection in symptomatic immunoglobulin 
deficiencies367, 368. 
Increased levels of anti-dsDNA IgG and IgA, which are ANAs routinely used in the diagnosis of 
SLE357, have previously been demonstrated in nasal polyps compared to CRSsNP and non-CRS 
control mucosa291. TLOs are a hallmark of severe inflammation in the context of auto-immune 
diseases and can be the local production site of ANAs271, 293. Therefore, we hypothesized that TLOs 
contribute to the perpetuating inflammation in CRSwNP by the local generation of ANAs. 
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However, our study did not provide a definitive answer to this question potentially because of the 
sub-detectable levels of immunoglobulins by immunoblot assays in our tissue lysate samples and 
the compatibility issue of tissue lysate samples with immunoblot assays, which are only guaranteed 
to work with serum or plasma samples. In the sera, there were no detectable ANAs in any of the 
tested subjects. These results indicate that TLO positivity in CRS is not associated with auto-
immunity. Further research is needed to determine the specificity of the local immunoglobulins 
within nasal polyps, as this may account for the increased disease severity in CRSwNP patients 
with TLOs.  
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Chapter 6: Conclusion 
In conclusion, this PhD thesis has advanced our understanding of the immunology in CRS. Firstly, 
we have identified the ectopic lymphoid structures termed TLOs in the nasal polyps of CRSwNP 
patients and found the positive correlation of the presence of TLOs with severe inflammation and 
recalcitrant disease in CRS. We have also identified the increased expression of genes important 
for TLO formation and maintenance in HNECs and immune cells in the subepithelial area, 
indicating that the nasal epithelium layer plays a critical role in mediating TLO formation in CRS. 
We also demonstrated that TLOs are correlated with lowered serum IgG levels in CRSwNP patients. 
Although the significance of this finding is unclear, it showed, for the first time, that CRS pathology 
could have a systemic influence on the immune system through TLOs. We hope that ongoing 
research in CRS immunology will ultimately yield a better understanding of the complex patho-
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